

Tuesday, August 26, 2025

Volume 56 No. 8



NOTICE – Items in this issue will be listed online weekly and printed monthly.

ACUMEN PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Cost & expenses	72,120	42,155
Operating income	(72,120)	(42,155)
Other income (expense), net	(193)	(122)
Gains or losses	150	1,050
Net income	(69,746)	(35,410)
Earnings common share		
Primary	\$(1.15)	\$(0.59)
Fully Diluted	\$(1.15)	\$(0.59)
Common Shares:		
Full Diluted	60,550	59,946
Year-end	60,573	60,080

ADVANCED FLOWER CAPITAL INC

Earnings, 6 mos. to Jun 30(Consol. – \$):

	2025	2024
Cost & expenses	23,900,913	13,105,451
Operating income	(7,381,156)	19,113,910
Gains or losses	(1,741,448)	(5,033,694)
Invest. income		(93,338)
Net before taxes	(9,122,604)	14,080,216
Income contin. oper.		13,635,881
Net income	(9,096,966)	16,392,005
Earnings common share		
Primary	\$(0.42)	\$0.79
Fully Diluted	\$(0.42)	\$0.79
Common Shares:		
Full Diluted	22,106,205	20,418,897
Year-end	22,595,111	20,667,094

AETHLON MEDICAL INC

Earnings, 3 mos. to Jun 30(Consol. – \$):

	2025	2024
Cost & expenses	1,792,390	2,620,858
Operating income	(1,792,390)	(2,620,858)
Other income (expense), net	(5,934)	
Net income	(1,761,858)	(2,571,440)
Earnings common share		
Primary	\$(0.85)	\$(2.72)
Fully Diluted	\$(0.85)	\$(2.72)
Common Shares:		
Full Diluted	2,076,416	932,236
Year-end	2,598,711	1,742,166

Consolidated Balance Sheet Items, as of (\$):

	2025	2024
Assets:		
Cash & equivalents	3,765,154	
Current assets	4,050,858	
Net property & equip.	593,720	
Total assets	5,306,002	
Liabilities:		
Current liabilities	1,627,437	
Stockholders' equity	3,423,513	
Net current assets	2,423,421	

AIRJOULE TECHNOLOGIES CORP

Earnings, 6 mos. to Jun 30(Consol. – \$):

	2025	2024
Cost & expenses	7,349,240	60,727,074
Operating income	(7,353,117)	(60,729,375)
Other income (expense), net	(4,605,415)	335,100,275
Gains or losses	25,622,106	4,859,000
Net before taxes	14,190,332	279,472,526
Income taxes	(3,201,539)	84,487,339
Net income	17,391,871	194,985,187
Earnings common share		
Primary	\$0.30	\$4.05
Fully Diluted	\$0.30	\$3.92

Common Shares:

Full Diluted	58,727,169	49,754,876
Year-end	60,439,593	55,775,670

ALAUNOS THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. – \$):

	2025	2024
Total Revenues	2,000	6,000
Cost & expenses	2,134,000	2,913,000
Operating income	(2,132,000)	(2,907,000)
Other income (expense), net	39,000	97,000
Gains or losses	(31,000)	
Net income	(2,124,000)	(2,810,000)
Earnings common share		
Primary	\$(1.30)	\$(1.75)
Fully Diluted	\$(1.30)	\$(1.75)

Common Shares:

Full Diluted	1,639,123	1,601,252
Year-end	2,074,746	1,601,252

ALICO, INC.

Earnings, 9 mos. to Jun 30(Consol. – \$):

	2025	2024
Total Revenues	43,264,000	45,708,000
Cost & expenses	238,096,000	90,442,000
Operating income	(194,832,000)	(44,734,000)
Other income (expense), net	255,000	
Gains or losses	21,400,000	81,520,000
Net before taxes	(175,882,000)	34,235,000
Income taxes	(36,874,000)	9,721,000
Net income	(139,008,000)	24,514,000
Earnings common share		
Primary	\$(18.18)	\$3.29
Fully Diluted	\$(18.18)	\$3.29

Common Shares:

Full Diluted	7,637,000	7,620,000
Year-end	7,642,085	7,624,185

ALLARITY THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Cost & expenses	7,169	7,611
Operating income	(7,169)	(7,611)
Gains or losses	1	2,662
Net before taxes		(5,476)
Income taxes		(4)
Net income	(5,052)	(5,472)
Balance for common		(5,549)
Earnings common share		
Primary	\$(0.38)	\$(0.73)
Fully Diluted	\$(0.38)	\$(0.73)

Common Shares:

Full Diluted	13,357	7,642
Year-end	14,620	35,039

ALT5 SIGMA CORP

Earnings, 6 mos. to (Consol. – \$):

	06/28/25	06/29/24
Total Revenues	11,892,000	2,169,000
Cost & expenses	15,617,000	5,753,000
Operating income	(3,725,000)	(3,584,000)
Other income (expense), net	(96,000)	158,000
Gains or losses	(2,879,000)	331,000
Net before taxes	(7,970,000)	(3,343,000)
Income taxes	(147,000)	(2,690,000)
Income contin. oper.	(7,823,000)	(653,000)
Net income	(11,976,000)	(1,555,000)
Earnings common share		
Primary	\$(0.70)	\$(0.18)

Fully Diluted \$(0.70) \$(0.18)

Common Shares:

Full Diluted	17,050,637	8,426,349
Year-end	20,455,923	12,589,015

ALUMIS INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues	20,055	
Cost & expenses	262,122	103,733
Operating income	(242,067)	(103,733)
Other income (expense), net	187,825	(49)
Gains or losses		(5,406)
Net before taxes	(48,203)	
Income taxes	(8,561)	
Net income	(39,642)	(106,357)
Earnings common share		
Primary	\$(0.61)	\$(2.05)
Fully Diluted	\$(0.61)	\$(2.05)

Common Shares:

Full Diluted	65,440	51,845
Year-end	104,042	51,845

ANI PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. – \$):

	2025	2024
Total Revenues	408,493,000	
Cost & expenses	322,235,000	220,606,000
Operating income	40,086,000	25,481,000
Other income (expense), net	1,937,000	(120,000)
Gains or losses	(589,000)	6,943,000
Net before taxes	30,512,000	23,048,000
Income taxes	6,282,000	7,128,000
Net income	24,230,000	15,920,000
Balance for common	21,049,000	13,608,000
Earnings common share		
Primary	\$1.07	\$0.71
Fully Diluted	\$1.05	\$0.70

Common Shares:

Full Diluted	20,177,000	19,561,000
Year-end	21,731,315	21,074,392

ANNEXON INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Cost & expenses	109,131	62,152
Operating income	(109,131)	(62,152)
Net income	(103,512)	(54,786)
Balance for common	(105,369)	
Earnings common share		
Primary	\$(0.71)	\$(0.43)
Fully Diluted	\$(0.71)	\$(0.43)
Common Shares:		
Full Diluted	148,215	126,403
Year-end	109,832	105,540

APPLIED THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2025	2024
Total Revenues		334
Cost & expenses	48,623	41,867
Operating income	(48,623)	(41,533)
Other income (expense), net	(58)	(62)
Gains or losses	4,541	(40,660)
Net income	(43,155)	(81,040)
Earnings common share		
Primary	\$(0.30)	\$(0.60)
Fully Diluted	\$(0.30)	\$(0.60)
Common Shares:		

Full Diluted.....	144,941	134,628	Subscription.....	4,930,604	3,924,389	...	basic.....	...	...	\$(1.90)
Year-end.....	141,938	114,846	Maintenance.....	...	177,230	...	Net income (loss)	...	...	
ARK RESTAURANTS CORP			Other.....	284,700	256,984	...	per class B share -	...	...	
Earnings, 9 mos. to (Consol. - \$000):			Total revenues.....	5,215,304	4,358,603	3,534,647	basic.....	...	...	\$(1.90)
	06/28/25	06/29/24	Cost of revenues	(1).....	894,851	803,495	Net income (loss)	...	...	
Total Revenues.....	128,428	140,139	Cost of revenues.....	...	...	Ⓜ633,765	per class A share -	...	...	\$(1.90)
Cost & expenses.....	128,327	135,733	Gross profit.....	4,320,453	3,555,108	2,900,882	diluted.....	...	...	
Operating income.....	(2,342)	1,225	Research & development	expenses.....	2,669,312	2,184,111	Ⓜ1,869,881	Net income (loss)	...	
Other income (expense), net.....	391	311	Marketing & sales	expenses.....	1,134,535	877,497	Ⓜ769,861	per class B share -	...	
Gains or losses.....	(2,245)	1,088	General & administrative	expenses.....	...	...	Ⓜ606,362	diluted.....	...	\$(1.90)
Net before taxes.....	5,019	(202)	General and administrative	expenses.....	646,998	610,577	...	Full-Time Employees	13,813	12,157
Income taxes.....	(7,264)	1,290	Total operating	expenses.....	...	...	3,246,104	(Period End).....	13,813	12,157
Net income.....			Operating income	(loss).....	(130,392)	(117,077)	(345,222)	Total number of	13,813	12,157
Earnings common share			Other income	(expense), net.....	(50,277)	(30,916)	14,501	employees.....	10,726	
Primary.....	\$(2.65)	\$0.16	Interest income.....	112,324	96,663	...	49,732	Number of class A	...	9
Fully Diluted.....	\$(2.65)	\$0.15	Interest income.....	...	...	...	30,550	common stockholders	...	...
Common Shares:			Interest expense.....	30,550	34,077	...	30,147	Number of class B	...	3
Full Diluted.....	3,605	3,628	Interest expense.....	...	...	...	...	common stockholders	...	...
Year-end.....	3,606	3,604	Income (loss)	before provision	for income taxes -	domestic.....	...	Foreign currency	...	...
ARQ INC			Income (loss)	before provision	for income taxes -	foreign.....	...	translation	...	...
Earnings, 6 mos. to Jun 30(Consol. - \$):			Income (loss)	before provision	for income taxes -	foreign.....	...	adjustments.....	...	(2,270)
	2025	2024	Income (loss)	before provision	for income taxes -	foreign.....	...	Basic Weighted	...	(5,283)
Total Revenues.....	55,831,000	47,145,000	Interest income.....	112,324	96,663	...	49,732	Average Shares used	261,787	259,133
Cost & expenses.....	52,058,000	48,171,000	Interest income.....	...	...	...	30,550	to Calculate EPS -	...	...
Operating income.....	(893,000)	(4,400,000)	Interest expense.....	30,550	34,077	...	30,147	(Company Level)....	...	...
Other income (expense), net.....	281,000	663,000	Income (loss)	before provision	for income taxes -	domestic.....	...	Basic EPS - Net Inc	...	...
Net before taxes.....	(5,357,000)	30,000	Income (loss)	before provision	for income taxes -	foreign.....	...	incl Extra Items	...	...
Income taxes.....	(1,930,000)	(5,387,000)	Income (loss)	before provision	for income taxes -	foreign.....	...	appl to Common -	...	...
Net income.....			Income (loss)	before provision	for income taxes -	foreign.....	...	(Company Level)....	\$(0.98)	\$(1.16)
Balance for common.....	(5,387,000)	...	Income (loss)	before provision	for income taxes -	foreign.....	...	Diluted Weighted	...	...
Earnings common share			Income (loss)	before provision	for income taxes -	foreign.....	...	Average Shares used	261,787	259,133
Primary.....	\$(0.05)	\$(0.16)	Income (loss)	before provision	for income taxes -	foreign.....	...	to Calculate EPS -	...	...
Fully Diluted.....	\$(0.05)	\$(0.16)	Income (loss)	before provision	for income taxes -	foreign.....	...	(Company Level)....	\$(0.98)	\$(1.16)
Common Shares:			Income (loss)	before provision	for income taxes -	foreign.....	...	Diluted.....	...	...
Full Diluted.....	41,415,000	33,229,000	Income (loss)	before provision	for income taxes -	foreign.....	...	EPS - Basic -	...	...
Year-end.....	42,578,058	35,996,496	Income (loss)	before provision	for income taxes -	foreign.....	...	excluding	...	...
ARTERIS INC			Income (loss)	before provision	for income taxes -	foreign.....	...	Extraordinary Items	...	...
Earnings, 6 mos. to Jun 30(Consol. - \$000):			Income (loss)	before provision	for income taxes -	foreign.....	...	Applicable to	...	...
	2025	2024	Income (loss)	before provision	for income taxes -	foreign.....	...	Common - Total.....	\$(0.98)	\$(1.16)
Total Revenues.....	33,034	27,522	Income (loss)	before provision	for income taxes -	foreign.....	...	EPS - Diluted -	...	...
Cost & expenses.....	48,990	44,097	Income (loss)	before provision	for income taxes -	foreign.....	...	excluding	...	...
Operating income.....	(15,956)	(16,575)	Income (loss)	before provision	for income taxes -	foreign.....	...	Extraordinary Items	...	...
Other income (expense), net.....	(91)	317	Income (loss)	before provision	for income taxes -	foreign.....	...	Applicable to	...	...
Net before taxes.....	(16,137)	(16,402)	Income (loss)	before provision	for income taxes -	foreign.....	...	Common - Total.....	\$(0.98)	\$(1.16)
Income taxes.....	1,114	1,345	Income (loss)	before provision	for income taxes -	foreign.....	...	Number of Common	11	14
Net income.....	(17,251)	(17,747)	Income (loss)	before provision	for income taxes -	foreign.....	...	Shareholders.....	...	...
Earnings common share			Income (loss)	before provision	for income taxes -	foreign.....	...	Ⓜ Including share-based payment expense - cost of revenues:	...	...
Primary.....	\$(0.42)	\$(0.47)	Income (loss)	before provision	for income taxes -	foreign.....	...	\$63,913,000; Ⓜ Including amortization of acquired intangible	...	...
Fully Diluted.....	\$(0.42)	\$(0.47)	Income (loss)	before provision	for income taxes -	foreign.....	...	assets - cost of revenues: \$22,853,000; Ⓜ Including share-	...	...
Common Shares:			Income (loss)	before provision	for income taxes -	foreign.....	...	based payment expense - research and development expenses:	...	...
Full Diluted.....	41,339	38,093	Income (loss)	before provision	for income taxes -	foreign.....	...	\$604,301,000; Ⓜ Including amortization of acquired intangible	...	...
Year-end.....	42,592	39,193	Income (loss)	before provision	for income taxes -	foreign.....	...	assets - research and development expenses: \$374,000; Ⓜ In-	...	...
ASTRONICS CORP			Income (loss)	before provision	for income taxes -	foreign.....	...	cluding share-based payment expense - marketing and sales ex-	...	...
Earnings, 6 mos. to (Consol. - \$000):			Income (loss)	before provision	for income taxes -	foreign.....	...	penses: \$131,739,000; Ⓜ Including amortization of acquired in-	...	...
	06/28/25	06/29/24	Income (loss)	before provision	for income taxes -	foreign.....	...	tangible assets - marketing and sales expenses: \$9,900,000; Ⓜ In-	...	...
Total Revenues.....	410,614	383,188	Income (loss)	before provision	for income taxes -	foreign.....	...	cluding share-based payment expense - general and administrative	...	...
Cost & expenses.....	392,719	373,972	Income (loss)	before provision	for income taxes -	foreign.....	...	expenses: \$148,134,000	...	...
Operating income.....	17,895	9,216	Income (loss)	before provision	for income taxes -	foreign.....	...	Consolidated Balance Sheet, Years Ended Jun. 30 (\$000):		
Other income (expense), net.....	377	(871)	Income (loss)	before provision	for income taxes -	foreign.....	...	2025	2024	
Net before taxes.....	12,025	(3,270)	Income (loss)	before provision	for income taxes -	foreign.....	...	Cash and cash equivalents.....	2,512,874	2,176,930
Income taxes.....	1,183	(1,625)	Income (loss)	before provision	for income taxes -	foreign.....	...	Marketable securities.....	424,268	161,973
Net income.....	10,842	(1,645)	Income (loss)	before provision	for income taxes -	foreign.....	...	Accounts receivable, net.....	778,302	628,049
Earnings common share			Income (loss)	before provision	for income taxes -	foreign.....	...	Prepaid expenses & other	...	...
Primary.....	\$0.31	\$(0.05)	Income (loss)	before provision	for income taxes -	foreign.....	...	current assets.....	175,793	109,312
Fully Diluted.....	\$0.30	\$(0.05)	Income (loss)	before provision	for income taxes -	foreign.....	...	Total current assets.....	3,891,237	3,076,264
Common Shares:			Income (loss)	before provision	for income taxes -	foreign.....	...	Equipment.....	15,008	11,200
Full Diluted.....	36,059	34,936	Income (loss)	before provision	for income taxes -	foreign.....	...	Computer hardware &	...	...
Year-end.....	35,406	34,992	Income (loss)	before provision	for income taxes -	foreign.....	...	software.....	25,217	40,824
ATLASSIAN CORP			Income (loss)	before provision	for income taxes -	foreign.....	...	Furniture & fittings.....	...	25,172
Annual Report			Income (loss)	before provision	for income taxes -	foreign.....	...	Leasehold Improvements ,	...	...
Consolidated Income Statement, Years Ended Jun. 30			Income (loss)	before provision	for income taxes -	foreign.....	...	Gross.....	154,113	137,944
(\$000):			Income (loss)	before provision	for income taxes -	foreign.....	...	Computer Hardware and	...	...
	2025	2024	2023	Income (loss)	before provision	for income taxes -	foreign.....	Software, Gross (PPE).....	58,559	...
Revenues -	...	...	2,922,576	Income (loss)	before provision	for income taxes -	foreign.....	Property & equipment,	252,897	215,140
subscription.....	...	...	2,922,576	Income (loss)	before provision	for income taxes -	foreign.....	gross.....	...	...
Revenues -	...	...	399,738	Income (loss)	before provision	for income taxes -	foreign.....	Acc Depr/Imp of Property	147,779	128,825
maintenance.....	...	...	212,333	Income (loss)	before provision	for income taxes -	foreign.....	and equipment.....	105,118	86,315
Revenues - other.....	...	...	212,333	Income (loss)	before provision	for income taxes -	foreign.....	Property and equipment,	...	...
	...	...	212,333	Income (loss)	before provision	for income taxes -	foreign.....	net.....	169,127	172,468
	...	...	212,333	Income (loss)	before provision	for income taxes -	foreign.....	Operating lease	...	...
	...	...	212,333	Income (loss)	before provision	for income taxes -	foreign.....	right-of-use assets.....	...	...

Strategic investments	221,942	223,221	Selling, general and administrative expenses	1,762,386	1,869,525	...	integration and other expenses	108,316	52,550	...
Intangible assets, net	244,840	299,057					Gain on legal settlements and other	...	(86,499)	...
Goodwill	1,304,445	1,288,756					Consolidated Balance Sheet, Years Ended (\$000):			
Deferred tax assets	3,762	3,934						06/28/25	06/29/24	
Other non-current assets	101,499	62,118								
Total assets	6,041,970	5,212,133				1,967,305				
Accounts payable	222,092	177,545								
Accrued expenses	180,197	149,046								
Employee benefits	422,986	332,518				28,038				
Tax liabilities	36,726	55,203								
Customer deposits	16,396	19,279		514,254	844,367	1,186,800				
Other payables	25,296	21,313		(17,283)	(15,736)	9,908				
Accrued expenses & other current liabilities	681,601	577,359								
Deferred revenue, current portion	2,227,002	1,806,269								
Operating lease liabilities, current portion	50,164	48,953		246,402	282,867	250,869				
Total current liabilities	3,180,859	2,610,126								
Deferred revenue, net of current portion	254,252	308,467								
Operating lease liabilities, net of current portion	201,483	214,474								
Term loan facility, net of current portion	987,684	985,911		5,104	4,519	7,865				
Deferred tax liabilities	23,881	20,387		90,637	94,663	173,450				
Other non-current liabilities	48,157	39,917								
Total liabilities	4,696,316	4,179,282		109,906	149,610	245,539				
Class A common stock	2	2								
Class B common stock	1	1								
Additional paid-in capital	5,574,290	4,212,064		3,509	(16,452)	(15,422)				
Accumulated other comprehensive income	13,226	25,300								
Accumulated deficit	(4,241,865)	(3,204,516)		2,714	86	2,606				
Total stockholders' equity (deficit)	1,345,654	1,032,851		(105,777)	320	(20,675)				
Total stockholders equity	1,345,654	1,032,851								
Recent Dividends:										
1. Atlassian Corp class B ordinary (nominal value: US\$0.010).										
No dividends paid.										
2. Atlassian Corp class A ordinary (nominal value: US\$0.010).										
No dividends paid.										
Annual Dividends:										
1. Atlassian Corp class B ordinary (nominal value: US\$0.010).										
No dividends paid.										
2. Atlassian Corp class A ordinary (nominal value: US\$0.010).										
No dividends paid.										
AURA BIOSCIENCES INC										
Earnings, 6 mos. to Jun 30(Consol. – \$000):										
	2025	2024								
Cost & expenses	57,648	45,077		\$2.78	\$5.51	...				
Operating income	(57,648)	(45,077)								
Other income (expense), net	(59)	(57)		\$2.78	\$5.51	\$8.37				
Net before taxes	(54,436)	(39,997)								
Income taxes	66	46								
Net income	(54,502)	(40,043)								
Earnings common share										
Primary	\$(1.01)	\$(0.81)		\$2.75	\$5.43	...				
Fully Diluted	\$(1.01)	\$(0.81)								
Common Shares:				\$2.75	\$5.43	\$8.26				
Full Diluted	54,093	49,500								
Year-end	62,071	49,583		\$1.32	\$1.24	...				
AVNET INC										
Annual Report										
Consolidated Income Statement, Years Ended (\$000):										
	06/28/25	06/29/24	07/01/23							
Sales	22,200,754	23,757,129	...							
Sales	...	...	26,536,881							
Total revenues	22,200,754	23,757,129	26,536,881							
Cost of sales	19,815,798	20,990,687	...							
Cost of sales	...	...	23,354,738							
Gross profit (loss)	2,384,956	2,766,442	3,182,143							

06/06/2023	0.29	05/22/2023	06/07/2023	06/21/2023
09/12/2023	0.31	08/29/2023	09/13/2023	09/27/2023
12/05/2023	0.31	11/15/2023	12/06/2023	12/20/2023
03/05/2024	0.31	02/16/2024	03/06/2024	03/20/2024
06/05/2024	0.31	05/16/2024	06/05/2024	06/18/2024
09/11/2024	0.33	08/19/2024	09/11/2024	09/25/2024
12/04/2024	0.33	11/21/2024	12/04/2024	12/18/2024
03/05/2025	0.33	02/21/2025	03/05/2025	03/19/2025
06/04/2025	0.33	05/15/2025	06/04/2025	06/18/2025

Annual Dividends:**1. Avnet Inc common.**

2022.....	1.10	2023.....	1.20	2024.....	1.28
2025.....	0.66				

AXT INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	37,330	50,611
Cost & expenses	54,350	55,843
Operating income	(17,020)	(5,232)
Other income (expense), net	454	3,011
Net before taxes	(17,037)	(2,852)
Income taxes	653	395
Net income	(17,690)	(3,247)
Balance for common	(15,894)	(3,687)
Earnings common share		
Primary	\$(0.36)	\$(0.09)
Fully Diluted	\$(0.36)	\$(0.09)
Common Shares:		
Full Diluted	43,630	43,039
Year-end	46,078	44,482

BEASLEY BROADCAST GROUP INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	101,912,176	114,816,003
Cost & expenses	97,780,164	106,876,394
Operating income	890,667	4,272,113
Other income (expense), net	1,698,372	627,265
Invest. income		6,026,776
Equity earnings	41,358	284
Net before taxes	(4,086,375)	(753,983)
Income taxes	(1,283,737)	(486,216)
Net income	(2,843,996)	(268,051)
Earnings common share		
Primary	\$(1.59)	\$(0.01)
Fully Diluted	\$(1.59)	\$(0.01)
Common Shares:		
Full Diluted	1,793,399	30,340,012
Year-end	1,803,994	30,459,355

BIOSIG TECHNOLOGIES INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues		27,000
Cost & expenses	22,773,000	8,629,000
Operating income	(23,350,000)	(8,729,000)
Other income (expense), net	168,000	1,411,000
Net income	(23,169,000)	(7,326,000)
Balance for common	(23,190,000)	(7,455,000)
Earnings common share		
Primary	\$(0.95)	\$(0.65)
Fully Diluted	\$(0.95)	\$(0.65)
Common Shares:		
Full Diluted	24,286,234	11,386,266
Year-end	30,793,135	15,110,846

BLUM HOLDINGS INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	5,718,000	5,569,000
Cost & expenses	7,829,000	15,572,000
Operating income	(2,111,000)	(10,003,000)
Other income (expense), net	526,000	15,691,000
Gains or losses	269,000	(483,000)
Net before taxes	(1,873,000)	4,078,000
Income taxes	578,000	314,000
Income contin. oper.		3,764,000
Net income	(2,451,000)	20,313,000
Earnings common share		
Primary	\$(0.27)	\$2.33
Fully Diluted	\$(0.27)	\$1.92
Common Shares:		

Full Diluted	12,307,664	10,811,340
Year-end	13,553,473	9,744,914

BOLT BIOTHERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	3,026	6,549
Cost & expenses	24,351	46,238
Operating income	(21,325)	(39,689)
Other income (expense), net	72	4,675
Net income	(19,610)	(32,006)
Earnings common share		
Primary	\$(10.22)	\$(16.80)
Fully Diluted	\$(10.22)	\$(16.80)
Common Shares:		
Full Diluted	1,917	1,905
Year-end	1,919	1,913

CADIZ INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	7,080	1,634
Cost & expenses	19,785	12,891
Operating income	(13,310)	(11,857)
Other income (expense), net	138	(274)
Net before taxes	(17,318)	(15,717)
Income taxes	5	5
Net income	(17,323)	(15,722)
Balance for common	(19,876)	(18,275)
Earnings common share		
Primary	\$(0.25)	\$(0.27)
Fully Diluted	\$(0.25)	\$(0.27)
Common Shares:		
Full Diluted	79,588	67,384
Year-end	81,896	67,800

CANDEL THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Cost & expenses	19,307	16,473
Operating income	(19,307)	(16,473)
Gains or losses	20,572	(13,332)
Net income	2,583	(30,458)
Earnings common share		
Primary	\$0.05	\$(1.03)
Fully Diluted	\$0.05	\$(1.03)
Common Shares:		
Full Diluted	53,370	29,538
Year-end	54,890	31,064

CANTERBURY PARK HOLDING CORP (NEW)**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	28,807,366	30,300,384
Cost & expenses	25,807,971	25,676,236
Operating income	1,081,489	2,884,089
Other income (expense), net	(2,962,766)	(2,026,746)
Net before taxes	(958,616)	1,928,440
Income taxes	(332,000)	592,000
Net income	(626,616)	1,336,440
Earnings common share		
Primary	\$(0.12)	\$0.27
Fully Diluted	\$(0.12)	\$0.27
Common Shares:		
Full Diluted	5,050,003	5,009,221
Year-end	5,086,028	5,007,921

CARIBOU BIOSCIENCES INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	5,020	5,893
Cost & expenses	95,511	95,396
Operating income	(90,491)	(89,503)
Other income (expense), net	(4,383)	8,576
Gains or losses	785	1,996
Net income	(94,089)	(78,931)
Earnings common share		
Primary	\$(1.01)	\$(0.88)
Fully Diluted	\$(1.01)	\$(0.88)
Common Shares:		
Full Diluted	92,855	89,822
Year-end	93,123	90,363

CENTURY THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	109,164	1,625
Cost & expenses	69,651	67,693
Operating income	39,513	(66,068)
Other income (expense), net	75	1
Net before taxes		(59,247)
Income taxes		22
Net income	44,019	(59,269)
Earnings common share		
Primary	\$0.51	\$(0.82)
Fully Diluted	\$0.51	\$(0.82)
Common Shares:		
Full Diluted	86,208	72,194
Year-end	86,322	84,552

CODEXIS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	22,871	25,052
Cost & expenses	56,219	59,672
Operating income	(33,348)	(34,620)
Other income (expense), net	(1,926)	(1,500)
Net before taxes	(33,939)	(34,239)
Income taxes	21	21
Net income	(33,960)	(34,260)
Earnings common share		
Primary	\$(0.40)	\$(0.49)
Fully Diluted	\$(0.40)	\$(0.49)
Common Shares:		
Full Diluted	83,908	70,115
Year-end	90,254	70,914

COHERENT CORP**Annual Report****Consolidated Income Statement, Years Ended Jun. 30 (\$000):**

	2025	2024	2023
Revenues	5,810,115	4,707,688	...
Revenues	...	...	5,160,100
Revenues	5,810,115	4,707,688	5,160,100
Cost of goods sold ...	3,766,793	3,251,724	...
Cost of goods sold ...	...	...	3,541,817
Internal research & development	581,924	478,788	499,603
Selling, general and administrative.	926,451	854,001	...
Selling, general & administrative	...	...	1,036,699
Interest Expense	243,251	288,475	...
Interest expense	...	...	286,872
Earnings (loss) before income taxes ..	94,181	(147,647)	(355,558)
Current federal income tax expense (benefit)	3,010	10,119	5
Current state income tax expense (benefit)	1,733	181	3,867
Current foreign income tax expense (benefit)	154,815	103,640	106,850
Total current income tax expense (benefit)	159,558	113,940	...
Deferred federal income tax expense (benefit)	(50,454)	(68,955)	(106,044)
Deferred state income tax expense (benefit)	(7,217)	(186)	(7,151)
Deferred foreign income tax expense (benefit)	(37,763)	(33,682)	(93,627)
Total deferred income tax expense (benefit)	(95,434)	(102,823)	...
Net Loss	30,057	(158,764)	...
Income tax expense (benefit)	64,124	11,117	(96,100)
Net earnings (loss) ..	30,057	(158,764)	(259,458)
Less: net earnings attributable to noncontrolling			

interests	19,307	2,610	...	depreciation	...	1,482,082	
Net earnings attributable to				Property, Plant & Equipment, net	1,877,507	...	
II-VI Incorporated ...	49,364	(156,154)	...	Property, plant & equipment, net	...	1,817,259	
Less: dividends on preferred stock	129,926	123,357	144,212	Goodwill	4,471,084	4,464,329	
Net earnings (loss) available to the common shareholder ..	(80,562)	(279,511)	(403,670)	Other intangible assets, net	3,204,747	...	
Weighted average shares outstanding - basic	154,755	151,642	137,578	Other intangible assets, net	...	3,503,247	
Weighted average shares outstanding - diluted	154,755	151,642	137,578	Deferred income taxes	53,407	40,966	
Year end shares outstanding	155,555	152,780	139,584	Other assets	662,221	313,089	
Earnings (loss) per share - continuing operations - basic	\$(0.52)	\$(1.84)	...	Restricted Cash, non-current	714,816	689,645	
Net earnings (loss) per share - basic	\$(0.52)	\$(1.84)	\$(2.93)	Total assets	14,910,936	14,488,634	
Earnings (loss) per share - continuing operations - diluted	\$(0.52)	\$(1.84)	...	Current portion of long-term debt	188,306	73,770	
Net earnings (loss) per share - diluted	\$(0.52)	\$(1.84)	\$(2.93)	Accounts Payable	846,984	631,548	
Full-Time Employees (Period End)	30,216	26,157	...	Accrued compensation & benefits	258,650	212,458	
Total number of employees	30,216	26,157	26,622	Operating lease current liabilities	41,575	40,580	
Number of common stockholders	790	906	918	Accrued income taxes payable	123,762	90,705	
Foreign currency translation adjustments	...	(81,889)	87,927	Contract liabilities	62,967	62,123	
Other expense (income), net	...	...	(31,566)	Other accrued liabilities	335,564	294,706	
Restructuring Charges	160,081	27,054	...	Year 1	2,771	2,697	
Restructuring charges	...	...	119,101	Accrued Expenses - Balancing value	269,826	229,886	
Dividends Per Share - Common - Gross - by Period End Date ..	...	...	\$12.00	Total current liabilities	1,794,841	1,343,767	
Other expense (income), net	(47,554)	(44,707)	...	Other long-term debt	3,498,615	4,026,448	
Total Costs, Expenses, & Other Expense (Income)	...	4,855,335	...	Deferred income taxes	711,717	784,374	
Impairment of assets held-for-sale	84,988	...	...	Operating lease liabilities	165,162	162,355	
				Other liabilities	259,318	225,411	
				Total liabilities	6,429,653	6,542,355	
				Series B redeemable convertible preferred stock	...	2,364,772	
				Common stock, no par value; authorized - 300,000,000 shares; issued - 104,043,057 shares at December 31, 2019; 76,315,337 shares at June 30, 2019	5,056,168	4,857,657	
				Foreign currency translation adjustment	381,554	(26,092)	
				Defined benefit pension plan	(13,535)	(7,184)	
				Hedging Reserves	4,018	35,916	
				Accumulated other comprehensive income (AOCI)	372,037	2,640	
				Retained earnings	584,374	664,940	
				Noncontrolling interests (NCI)	...	371,392	
				Series B redeemable convertible preferred stock	2,483,261	...	
				Noncontrolling interests (NCI)	353,508	...	
				Treasury Stock	368,065	315,122	
				Total shareholders' equity (deficit)	8,481,283	5,210,115	
				Total shareholders' equity	8,481,283	5,581,507	

Consolidated Balance Sheet, Years Ended Jun. 30 (\$000):

2025 2024

Cash and cash equivalents	909,200	926,033
Accounts receivable, gross	976,240	858,053
Less: allowance for doubtful accounts	12,189	9,511
Accounts receivable	964,051	848,542
Raw materials	394,682	429,888
Work in progress	824,360	620,575
Finished goods	218,594	235,941
Inventories	1,437,636	1,286,404
Prepaid and refundable income taxes	55,773	26,909
Prepaid and other current assets	551,597	398,203
Restricted cash, current	8,897	174,008
Total current assets	3,927,154	3,660,099
Land and improvements	59,543	66,156
Buildings & improvements	881,578	774,991
Machinery & equipment	2,188,509	2,034,310
Construction in progress	363,129	398,884
Finance lease right-of-use asset	3,492,759	3,299,341
Finance lease right-of-use asset	...	25,000
accumulated depreciation	1,615,252	...
Less accumulated		

Recent Dividends:

1. Coherent Corp 5% series B redeemable convertible preferred.
No dividends paid.
2. Coherent Corp 6% cumulative series A mandatory convertible preferred.

ExDate	Amt	Declared	Record	Payable
12/14/2021	3.00	11/19/2021	12/15/2021	01/01/2022
	3.00	02/18/2022	03/15/2022	04/01/2022
06/14/2022	3.00	05/20/2022	06/15/2022	07/01/2022
09/14/2022	3.00	08/31/2022	09/15/2022	10/01/2022
12/14/2022	3.00	11/22/2022	12/15/2022	01/01/2023
03/14/2023	3.00	02/23/2023	03/15/2023	04/03/2023
06/14/2023	3.00	05/09/2023	06/15/2023	07/03/2023

3. Coherent Corp common.

No dividends paid.

Annual Dividends:

1. Coherent Corp 5% series B redeemable convertible preferred.
No dividends paid.
2. Coherent Corp 6% cumulative series A mandatory convertible preferred.

2022 12.00 2023 9.00

3. Coherent Corp common.

No dividends paid.

COINBASE GLOBAL INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2025	2024
Total Revenues	3,531,503,000	3,087,198,000
Cost & expenses	2,850,347,000	1,983,620,000
Operating income	681,156,000	1,103,578,000
Other income (expense), net	29,212,000	7,839,000
Invest. income	1,236,907,000	305,348,000
Net before taxes	1,906,229,000	1,377,187,000
Income taxes	411,721,000	164,792,000
Net income	1,494,508,000	1,212,395,000
Balance for common	...	1,211,611,000
Earnings common share		
Primary	\$5.87	\$4.95
Fully Diluted	\$5.39	\$4.49
Common Shares:		
Full Diluted	278,700,000	271,003,000
Year-end	256,433,000	248,337,000

CONIFER HOLDINGS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2025	2024
Cost & expenses	28,031	37,425
Operating income	2,573	(2,643)
Net before taxes	...	(2,643)
Income taxes	...	(484)
Income contin. oper.	...	(2,159)
Net income	2,573	(3,561)
Balance for common	2,573	(3,876)
Earnings common share		
Primary	\$0.21	\$(0.32)
Fully Diluted	\$0.21	\$(0.32)
Common Shares:		
Full Diluted	12,223	12,223
Year-end	12,223	12,223

CRESCENT CAPITAL BDC INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2025	2024
Cost & expenses	50,712,000	53,493,000
Operating income	34,409,000	45,819,000
Other income (expense), net	(5,187,000)	7,602,000
Gains or losses	(99,000)	2,704,000
Invest. income	(9,305,000)	(6,935,000)
Net before taxes	19,818,000	49,190,000
Income taxes	901,000	800,000
Net income	18,917,000	48,390,000
Earnings common share		
Primary	\$0.51	\$1.21
Fully Diluted	\$0.51	\$1.21
Common Shares:		
Full Diluted	37,061,547	37,061,547
Year-end	37,061,547	37,061,547

DAWSON GEOPHYSICAL CO (NEW)

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2025	2024
Total Revenues	44,096,000	
Cost & expenses	24,821,000	39,068,000
Operating income	(1,337,000)	2,033,000
Other income (expense), net	71,000	205,000
Net before taxes	(1,361,000)	2,371,000
Net income	(1,357,000)	2,300,000
Earnings common share		
Primary	\$(0.04)	\$0.07
Fully Diluted	\$(0.04)	\$0.07
Common Shares:		
Full Diluted	30,985,212	30,813,886
Year-end	31,047,801	30,906,777

DIGIMARC CORP

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2025	2024
Total Revenues	17,378	20,317
Cost & expenses	37,324	40,613
Operating income	(20,505)	(20,839)
Other income (expense), net	579	250
Net before taxes	(19,926)	(19,588)
Income taxes	24	20
Net income	(19,950)	(19,608)
Earnings common share		
Primary	\$(0.93)	\$(0.93)
Fully Diluted	\$(0.93)	\$(0.93)
Common Shares:		
Full Diluted	21,565	21,061
Year-end	21,657	21,420

DIXIE GROUP INC.**Earnings, 6 mos. to (Consol. – \$000):**

	06/28/25	06/29/24
Total Revenues	131,563	135,761
Cost & expenses	128,363	134,324
Operating income	3,200	1,437
Other income (expense), net	(84)	(8)
Net before taxes	(249)	(1,723)
Income taxes	79	20
Income contin. oper.	(328)	(1,743)
Net income	(537)	(1,891)
Earnings common share		
Primary	\$(0.03)	\$(0.13)
Fully Diluted	\$(0.03)	\$(0.13)
Common Shares:		
Full Diluted	14,431	14,872
Year-end	15,217	15,587

DRILLING TOOLS INTERNATIONAL CORP**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	82,301,000	74,507,000
Cost & expenses	63,774,000	56,095,000
Operating income	(3,489,000)	7,365,000
Other income (expense), net	(5,747,000)	(2,798,000)
Gains or losses	(72,000)	771,000
Net before taxes	(3,489,000)	4,346,000
Income taxes	587,000	854,000
Net income	(4,076,000)	3,492,000
Earnings common share		
Primary	\$(0.11)	\$0.12
Fully Diluted	\$(0.11)	\$0.12
Common Shares:		
Full Diluted	35,583,139	30,321,002
Year-end	35,661,297	29,859,564

EMPIRE PETROLEUM CORP**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	17,756,000	22,185,483
Cost & expenses	21,813,000	24,341,825
Operating income	(8,859,000)	(6,323,453)
Other income (expense), net	212,000	(991,245)
Net income	(9,277,000)	(8,364,967)
Earnings common share		
Primary	\$(0.27)	\$(0.30)
Fully Diluted	\$(0.27)	\$(0.30)
Common Shares:		
Full Diluted	33,837,377	27,752,816
Year-end	33,756,595	31,375,375

ENACT HOLDINGS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Cost & expenses	156,522	107,574
Operating income	425,923	440,750
Other income (expense), net	(10,930)	(10,930)
Net before taxes	425,923	440,750
Income taxes	92,337	96,089
Net income	333,586	344,661
Earnings common share		
Primary	\$2.21	\$2.18
Fully Diluted	\$2.20	\$2.16
Common Shares:		
Full Diluted	151,818	159,329
Year-end	148,385	156,111

ENANTA PHARMACEUTICALS INC**Earnings, 9 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	50,199	53,028
Cost & expenses	117,162	144,865
Operating income	(66,963)	(91,837)
Net before taxes	(64,881)	(88,602)
Income taxes	(1,692)	(1,380)
Net income	(63,189)	(87,222)
Earnings common share		
Primary	\$(2.96)	\$(4.12)
Fully Diluted	\$(2.96)	\$(4.12)
Common Shares:		
Full Diluted	21,322	21,145
Year-end	21,378	21,182

EQUILLIUM INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	24,542,000	24,542,000
Cost & expenses	15,098,000	27,434,000
Operating income	(15,098,000)	(2,892,000)
Other income (expense), net	410,000	(185,000)
Net income	(14,393,000)	(2,266,000)
Earnings common share		
Primary	\$(0.40)	\$(0.06)
Fully Diluted	\$(0.40)	\$(0.06)
Common Shares:		
Full Diluted	35,653,455	35,273,394
Year-end	35,719,317	35,424,388

ERASCA INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Cost & expenses	73,755	106,633
Operating income	(73,755)	(106,633)
Other income (expense), net	(157)	(526)
Net income	(64,842)	(98,218)
Earnings common share		
Primary	\$(0.23)	\$(0.53)
Fully Diluted	\$(0.23)	\$(0.53)
Common Shares:		
Full Diluted	283,308	184,484
Year-end	283,650	273,040

ESPERION THERAPEUTICS INC (NEW)**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	147,380,000	211,569,000
Cost & expenses	162,381,000	136,721,000
Operating income	(15,001,000)	74,848,000
Other income (expense), net	1,738,000	(48,004,000)
Net income	(53,180,000)	(903,000)
Earnings common share		
Primary	\$(0.27)	\$(0.01)
Fully Diluted	\$(0.27)	\$(0.01)
Common Shares:		
Full Diluted	196,841,011	179,026,191
Year-end	200,155,266	194,625,408

EUROPEAN WAX CENTER INC**Earnings, 6 mos. to (Consol. – \$000):**

	07/05/25	07/06/24
Total Revenues	107,338	111,745
Cost & expenses	72,703	76,108
Operating income	24,651	25,652
Other income (expense), net	(20)	(249)
Net before taxes	11,404	12,700
Income taxes	3,441	2,971
Net income	7,963	9,729
Earnings common share		
Primary	\$0.13	\$0.15
Fully Diluted	\$0.13	\$0.15
Common Shares:		
Full Diluted	43,383	48,425
Year-end	43,361	47,712

EXTREME NETWORKS INC**Annual Report****Consolidated Income Statement, Years Ended Jun. 30 (\$000):**

	2025	2024	2023
Sales and marketing ..	327,563	345,802	...
General and administrative	139,621	99,938	...

Product	...	699,257	...
Service	435,605	417,946	...
Net Revenues	704,462	...	...
Product	...	...	932,454
Service and subscription	...	...	380,000
Total net revenues	1,140,067	1,117,203	1,312,454
Product	300,831	365,759	...
Service And Subscription	130,109	120,613	...
Product	...	...	426,295
Service and subscription	...	...	131,439
Total cost of revenues	430,940	486,372	557,734
Total gross profit (loss)	709,127	630,831	754,720
Research & development expenses	221,459	211,931	214,270
Sales & marketing expenses	...	...	336,906
General & administrative expenses	...	...	89,934
Acquisition & integration costs	...	...	390
Restructuring & related charges	1,492	36,321	2,860
Amortization of intangibles	2,043	2,041	2,047
Operating income (loss)	16,949	(65,202)	108,313
Interest Income	4,313	4,556	...
Interest income	...	...	3,155
Interest Expense	15,928	16,986	...
Interest expense	...	...	17,385
Other income (expense), net	(1,061)	133	23
Income (loss) before income taxes	...	...	(2,179)
- domestic	...	...	(2,179)
Income (loss) before income taxes	...	...	96,285
- foreign	...	...	96,285
Income (loss) before income taxes ..	4,273	(77,499)	94,106
Current federal provision (benefit) for income taxes	2,921	1,340	3,221
Current state provision (benefit) for income taxes	1,066	246	3,640
Current foreign provision (benefit) for income taxes	8,932	6,843	9,086
Total current provision (benefit) for income taxes	12,919	8,429	...
Deferred federal provision (benefit) for income taxes	412	404	368
Deferred state provision (benefit) for income taxes	251	252	433
Deferred foreign provision (benefit) for income taxes	(1,842)	(620)	(716)
Total deferred provision (benefit) for income taxes	(1,179)	36	...
Net Income After Taxes	(7,467)	(85,964)	...
Provision (benefit) for income taxes	11,740	8,465	16,032
Net income (loss)	(7,467)	(85,964)	78,074
Weighted average shares outstanding			
- basic	132,331	129,288	129,473
Weighted average shares outstanding			
- diluted	132,331	129,288	133,649
Year end shares outstanding	132,064	130,284	127,775

[illegible]

No dividends paid.

Annual Dividends:**1. FRMO Corp. series R preferred.**

No dividends paid.

2. FRMO Corp. common.

No dividends paid.

FTAC EMERALD ACQUISITION CORP**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	15,263,763	
Cost & expenses	30,891,742	1,352,759
Operating income	(15,825,887)	(1,352,759)
Other income (expense), net	(6,807,290)	(838,825)
Gains or losses	(9,569,109)	
Net before taxes	(35,448,773)	(701,822)
Income taxes	4,859	346,027
Net income	(35,453,632)	(1,047,849)
Earnings common share		
Primary	\$(0.98)	\$(0.07)
Fully Diluted	\$(0.98)	\$(0.07)
Common Shares:		
Full Diluted	36,062,784	15,603,598
Year-end	46,571,343	14,349,106

FTAI INFRASTRUCTURE INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	218,447	167,422
Cost & expenses	173,297	141,125
Operating income	9,643	(96,365)
Other income (expense), net	5,991	(24,532)
Gains or losses	119,828	(163)
Net before taxes	9,643	(96,365)
Net income	50,205	(98,437)
Balance for common	24,359	(110,932)
Earnings common share		
Primary	\$0.21	\$(1.06)
Fully Diluted	\$0.21	\$(1.06)
Common Shares:		
Full Diluted	115,260	104,612
Year-end	115,088	101,705

GAIA INC (NEW)**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	48,472,000	43,169,000
Cost & expenses	51,682,000	46,016,000
Operating income	(3,210,000)	(2,847,000)
Net before taxes	(3,222,000)	
Income taxes	49,000	
Income contin. oper.	(3,271,000)	(3,099,000)
Net income	(3,266,000)	(3,134,000)
Earnings common share		
Primary	\$(0.11)	\$(0.14)
Fully Diluted	\$(0.11)	\$(0.14)
Common Shares:		
Full Diluted	24,686,000	23,267,000
Year-end	25,039,116	23,381,031

GALERA THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Cost & expenses	3,098	8,786
Operating income	(3,098)	(8,445)
Gains or losses	294	
Net income	(2,667)	(8,445)
Earnings common share		
Primary	\$(0.03)	\$(0.16)
Fully Diluted	\$(0.03)	\$(0.16)
Common Shares:		
Full Diluted	98,503	54,392
Year-end	75,462	54,392

GLADSTONE INVESTMENT CORP**Earnings, 3 mos. to Jun 30(Consol. – \$):**

	2025	2024
Cost & expenses	14,456,000	9,764,000
Operating income	7,772,000	(6,526,000)
Other income (expense), net	(1,316,000)	(18,942,000)
Invest. income		2,000
Net income	7,772,000	(6,526,000)
Earnings common share		
Primary	\$0.21	\$(0.18)
Fully Diluted	\$0.21	\$(0.18)

Common Shares:

Full Diluted	36,908,943	36,688,667
Year-end	37,352,676	36,688,667

Consolidated Balance Sheet Items, as of (\$):

	2025	
Assets:		
Cash & equivalents	4,118,000	
Current assets	11,241,000	
Total assets	1,053,909,000	
Liabilities:		
Current liabilities	48,715,000	
Long-term debt	518,625,000	
Stockholders' equity	485,304,000	
Net current assets	(37,474,000)	

GLOBAL WATER RESOURCES INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	26,698	25,120
Cost & expenses	16,178	15,126
Operating income	3,875	4,064
Other income (expense), net	1,787	1,774
Net before taxes	3,003	3,269
Income taxes	800	848
Net income	2,203	2,421
Earnings common share		
Primary	\$0.08	\$0.10
Fully Diluted	\$0.08	\$0.10
Common Shares:		
Full Diluted	25,987	24,306
Year-end	27,473	24,217

GOHEALTH INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	315,020	291,470
Cost & expenses	360,709	289,084
Operating income	(92,717)	(44,642)
Other income (expense), net	590	(82)
Net before taxes	(125,026)	(80,771)
Income taxes	749	(111)
Net income	(125,775)	(80,660)
Balance for common	(60,613)	(37,011)
Earnings common share		
Primary	\$(5.72)	\$(3.76)
Fully Diluted	\$(5.72)	\$(3.76)
Common Shares:		
Full Diluted	10,603	9,844
Year-end	11,213	10,058

GREENLANE HOLDINGS INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	2,257,000	7,578,000
Cost & expenses	8,682,000	14,603,000
Operating income	(6,732,000)	(7,475,000)
Other income (expense), net	41,000	3,163,000
Net income	(7,082,000)	(5,123,000)
Earnings common share		
Primary	\$(13.92)	\$(10,267.50)
Fully Diluted	\$(13.92)	\$(10,267.50)
Common Shares:		
Full Diluted	508,494	497
Year-end	1,386,551	705

GSI TECHNOLOGY INC**Earnings, 3 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	6,283	4,671
Cost & expenses	8,459	3,591
Operating income	(2,176)	1,080
Net before taxes	(2,163)	1,135
Income taxes	54	57
Net income	(2,217)	1,078
Earnings common share		
Primary	\$(0.08)	\$0.04
Fully Diluted	\$(0.08)	\$0.04
Common Shares:		
Full Diluted	26,967	25,686
Year-end	29,091	25,446

Consolidated Balance Sheet Items, as of (\$000):

	2025	
Assets:		
Cash & equivalents	22,725	
Inventories	3,763	
Current assets	31,087	

Net property & equip.	722	
Total assets	50,505	
Liabilities:		
Current liabilities	5,372	
Stockholders' equity	37,374	
Net current assets	25,715	

GULF ISLAND FABRICATION, INC.**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	77,811	84,143
Cost & expenses	75,610	77,152
Operating income	2,201	6,991
Net before taxes	3,260	8,136
Income taxes	7	7
Net income	3,253	8,129
Earnings common share		
Primary	\$0.20	\$0.50
Fully Diluted	\$0.20	\$0.48
Common Shares:		
Full Diluted	16,542	16,810
Year-end	16,041	16,516

GULF RESOURCES INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	9,948,232	3,690,231
Cost & expenses	15,309,125	14,106,647
Operating income	(5,360,893)	(10,416,416)
Other income (expense), net	(3,212)	(29,173,011)
Net before taxes		(39,568,220)
Net income	(5,403,277)	(37,090,050)
Earnings common share		
Primary	\$(0.43)	\$(3.46)
Fully Diluted	\$(0.43)	\$(3.46)
Common Shares:		
Full Diluted	12,520,613	10,726,924
Year-end	13,346,618	10,726,924

HARROW INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	111,573,000	
Cost & expenses	111,396,000	88,924,000
Operating income	177,000	(5,398,000)
Other income (expense), net	(6,000)	72,000
Gains or losses		(3,171,000)
Net before taxes		(19,383,000)
Income taxes		655,000
Net income	(12,785,000)	(20,038,000)
Earnings common share		
Primary	\$(0.35)	\$(0.56)
Fully Diluted	\$(0.35)	\$(0.56)
Common Shares:		
Full Diluted	36,304,787	35,544,312
Year-end	36,714,679	35,479,492

HARTE HANKS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	80,192	90,483
Cost & expenses	78,070	86,667
Operating income	(6)	1,748
Other income (expense), net	(900)	(38,778)
Net before taxes	(1,020)	(37,080)
Income taxes	(293)	(9,075)
Net income	(727)	(28,005)
Earnings common share		
Primary	\$(0.10)	\$(3.86)
Fully Diluted	\$(0.10)	\$(3.86)
Common Shares:		
Full Diluted	7,371	7,246
Year-end	7,406	7,280

HUDSON GLOBAL INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	67,407	69,603
Cost & expenses	68,814	72,146
Operating income	(1,935)	(3,227)
Other income (expense), net	(257)	(134)
Net before taxes	(2,067)	(3,174)
Income taxes	377	165
Net income	(2,444)	(3,339)

Earnings common share		
Primary	\$(0.82)	\$(1.10)
Fully Diluted	\$(0.82)	\$(1.10)
Common Shares:		
Full Diluted	2,990	3,026
Year-end	2,755	2,751

HYDROFARM HOLDINGS GROUP INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Total Revenues	79,779,000	108,965,000
Cost & expenses	104,111,000	136,989,000
Operating income	(24,332,000)	(28,024,000)
Other income (expense), net	(162,000)	294,000
Net before taxes	(31,262,000)	(35,472,000)
Income taxes	(16,000)	586,000
Net income	(31,246,000)	(36,058,000)
Earnings common share		
Primary	\$(6.75)	\$(7.90)
Fully Diluted	\$(6.75)	\$(7.90)
Common Shares:		
Full Diluted	4,630,390	4,589,634
Year-end	4,659,020	4,598,032

IDENTIV INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	10,309	13,399
Cost & expenses	22,164	25,182
Operating income	(11,855)	(12,304)
Net before taxes	(10,723)	(12,304)
Income taxes	108	1
Income contin. oper.		(12,305)
Net income	(10,831)	(10,774)
Balance for common	(11,241)	(11,255)
Earnings common share		
Primary	\$(0.47)	\$(0.48)
Fully Diluted	\$(0.47)	\$(0.48)
Common Shares:		
Full Diluted	23,679	23,413
Year-end	23,658	23,448

IMMUNEERING CORP**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Cost & expenses	30,227,911	30,224,865
Operating income	(30,242,544)	(30,239,498)
Other income (expense), net		220,754
Net income	(29,480,012)	(28,387,756)
Earnings common share		
Primary	\$(0.82)	\$(0.96)
Fully Diluted	\$(0.82)	\$(0.96)
Common Shares:		
Full Diluted	35,759,026	29,511,856
Year-end	35,987,306	29,653,355

INHIBRX INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	1,300	100
Cost & expenses	71,590	234,823
Operating income	(70,290)	(234,723)
Other income (expense), net	(296)	2,021,472
Net before taxes	(71,963)	1,779,303
Income taxes	2	2
Net income	(71,965)	1,779,301
Earnings common share		
Primary	\$(4.65)	\$125.93
Fully Diluted	\$(4.65)	\$122.75
Common Shares:		
Full Diluted	15,468	14,495
Year-end	14,476	14,476

INOPIO PHARMACEUTICALS INC.**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Total Revenues	65,343	100,762
Cost & expenses	48,200,391	64,782,644
Operating income	(48,135,048)	(64,681,882)
Other income (expense), net	767,839	(1,134,959)
Gains or losses	2,734,385	480,057
Net income	(43,214,109)	(62,706,969)
Earnings common share		
Primary	\$(1.12)	\$(2.48)

Fully Diluted	\$(1.12)	\$(2.48)
Common Shares:		
Full Diluted	38,722,451	25,244,657
Year-end	36,718,527	25,963,544

INSEGO CORP**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Total Revenues	71,896,000	89,125,000
Cost & expenses	67,215,000	83,272,000
Operating income	856,000	(1,091,000)
Other income (expense), net	464,000	(347,000)
Net before taxes	(618,000)	(5,302,000)
Income taxes	45,000	135,000
Income contin. oper.	(663,000)	(5,437,000)
Net income	(1,063,000)	(3,831,000)
Balance for common	(2,810,000)	(5,429,000)
Earnings common share		
Primary	\$(0.19)	\$(0.46)
Fully Diluted	\$(0.19)	\$(0.46)
Common Shares:		
Full Diluted	15,012,918	11,887,233
Year-end	15,042,827	11,910,151

INSTIL BIO INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Cost & expenses	54,002,000	38,090,000
Operating income	(54,002,000)	(38,090,000)
Other income (expense), net	4,869,000	(1,130,000)
Net income	(49,594,000)	(39,219,000)
Earnings common share		
Primary	\$(7.55)	\$(6.03)
Fully Diluted	\$(7.55)	\$(6.03)
Common Shares:		
Full Diluted	6,564,994	6,503,913
Year-end	6,750,716	6,503,913

INTELLICHECK INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Total Revenues	10,017,000	9,352,000
Cost & expenses	10,663,000	10,076,000
Operating income	(646,000)	(724,000)
Net before taxes		(567,000)
Income taxes		2,000
Net income	(569,000)	(569,000)
Earnings common share		
Primary	\$(0.03)	\$(0.03)
Fully Diluted	\$(0.03)	\$(0.03)
Common Shares:		
Full Diluted	19,357,364	19,380,605
Year-end	20,025,843	19,492,702

INTERLINK ELECTRONICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	6,078	6,022
Cost & expenses	6,861	7,086
Operating income	(783)	(1,064)
Other income (expense), net	30	48
Net before taxes	(753)	(1,016)
Income taxes	(48)	32
Net income	(705)	(1,048)
Balance for common	(905)	(1,248)
Earnings common share		
Primary	\$(0.09)	\$(0.13)
Fully Diluted	\$(0.09)	\$(0.13)
Common Shares:		
Full Diluted	9,864	9,860
Year-end	9,864	9,860

INTERNATIONAL ISOTOPES INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Total Revenues	6,894,220	6,073,691
Cost & expenses	7,094,077	6,520,011
Operating income	(199,857)	(446,320)
Other income (expense), net	52,444	155,376
Net income	(273,479)	(387,496)
Earnings common share		
Common Shares:		
Full Diluted	525,718,720	521,473,413
Year-end	528,010,308	522,957,618

INVIVYD INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	23,090	2,264
Cost & expenses	55,072	97,600
Operating income	(31,982)	(95,336)
Other income (expense), net	1,033	4,593
Net income	(30,949)	(90,743)
Earnings common share		
Primary	\$(0.26)	\$(0.77)
Fully Diluted	\$(0.26)	\$(0.77)
Common Shares:		
Full Diluted	119,950	117,490
Year-end	120,143	119,443

IO BIOTECH INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Cost & expenses	45,754	41,730
Operating income	(45,754)	(41,730)
Gains or losses	(2,587)	
Net before taxes	(48,374)	(39,354)
Income taxes	264	789
Net income	(48,638)	(40,143)
Earnings common share		
Primary	\$(0.74)	\$(0.61)
Fully Diluted	\$(0.74)	\$(0.61)
Common Shares:		
Full Diluted	65,881	65,881
Year-end	65,881	65,881

IRIDEX CORP.**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	06/28/25	06/29/24
Total Revenues	25,467	24,392
Cost & expenses	26,612	30,322
Operating income	(1,145)	(5,930)
Other income (expense), net	(1,502)	(156)
Net before taxes	(2,647)	(6,086)
Income taxes	33	57
Net income	(2,680)	(6,143)
Earnings common share		
Primary	\$(0.16)	\$(0.38)
Fully Diluted	\$(0.16)	\$(0.38)
Common Shares:		
Full Diluted	16,760	16,270
Year-end	16,815	16,449

JOINT CORP (NEW)**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Total Revenues	26,347,860	24,794,752
Cost & expenses	27,400,336	26,328,585
Operating income	(1,816,701)	(2,205,921)
Other income (expense), net	345,839	116,730
Net before taxes	(1,470,862)	(2,089,191)
Income taxes	24,794	19,751
Income contin. oper.	(1,495,656)	(2,108,942)
Net income	1,061,159	(2,649,419)
Earnings common share		
Primary	\$0.07	\$(0.18)
Fully Diluted	\$0.07	\$(0.18)
Common Shares:		
Full Diluted	15,256,755	14,875,718
Year-end	15,330,728	14,963,772

KALARIS THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Cost & expenses	22,610	6,750
Operating income	(22,610)	(6,750)
Other income (expense), net	913	(2,041)
Gains or losses	1,594	311
Net income	(21,546)	(9,057)
Earnings common share		
Primary	\$(1.89)	\$(6.87)
Fully Diluted	\$(1.89)	\$(6.87)
Common Shares:		
Full Diluted	11,418	1,319
Year-end	18,702	115,312

KATAPULT HOLDINGS INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Total Revenues	143,832,000	123,924,000
Cost & expenses	145,778,000	122,745,000
Operating income	(1,946,000)	1,179,000
Other income (expense), net	(1,040,000)	
Gains or losses	(25,000)	(53,000)
Net before taxes	(13,433,000)	(7,392,000)
Income taxes	90,000	66,000
Net income	(13,523,000)	(7,458,000)
Earnings common share		
Primary	\$(2.87)	\$(1.75)
Fully Diluted	\$(2.87)	\$(1.75)
Common Shares:		
Full Diluted	4,716,000	4,264,000
Year-end	4,569,546	4,168,919

KEZAR LIFE SCIENCES INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	32,228	47,094
Operating income	(32,228)	(47,094)
Net income	(30,260)	(43,205)
Earnings common share		
Primary	\$(4.14)	\$(0.59)
Fully Diluted	\$(4.14)	\$(0.59)
Common Shares:		
Full Diluted	7,308	72,823
Year-end	7,316	72,888

KLX ENERGY SERVICES HOLDINGS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	313,000	354,900
Cost & expenses	291,000	321,600
Operating income	(26,400)	(11,700)
Net before taxes	(47,400)	(29,800)
Income taxes	400	400
Net income	(47,800)	(30,200)
Earnings common share		
Primary	\$(2.63)	\$(1.86)
Fully Diluted	\$(2.63)	\$(1.86)
Common Shares:		
Full Diluted	18,200	16,200
Year-end	17,800	16,800

KNIGHTSCOPE INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	5,666,000	5,457,000
Cost & expenses	18,762,000	20,498,000
Operating income	(13,096,000)	(15,041,000)
Other income (expense), net	24,000	(80,000)
Gains or losses		1,451,000
Net income	(13,226,000)	(13,863,000)
Earnings common share		
Primary	\$(2.13)	\$(0.13)
Fully Diluted	\$(2.13)	\$(0.13)
Common Shares:		
Full Diluted	6,204,242	106,099,552
Year-end	7,433,109	133,693,155

KODIAK SCIENCES INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	114,583	94,038
Operating income	(114,583)	(94,038)
Other income (expense), net	(34)	(425)
Net income	(111,774)	(88,156)
Earnings common share		
Primary	\$(2.12)	\$(1.68)
Fully Diluted	\$(2.12)	\$(1.68)
Common Shares:		
Full Diluted	52,763	52,532
Year-end	52,822	52,615

KVH INDUSTRIES, INC.**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	52,037,000	57,940,000
Cost & expenses	54,650,000	64,627,000
Operating income	(2,613,000)	(6,687,000)
Other income (expense), net	817,000	(564,000)
Net before taxes	(650,000)	(5,464,000)
Income taxes	130,000	75,000

Net income	(780,000)	(5,539,000)
Earnings common share		
Primary	\$(0.04)	\$(0.29)
Fully Diluted	\$(0.04)	\$(0.29)
Common Shares:		
Full Diluted	19,446,000	19,333,000
Year-end	19,525,435	19,714,086

LARIMAR THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	58,979	41,333
Operating income	(58,979)	(41,333)
Other income (expense), net	3,516	5,052
Net income	(55,463)	(36,281)
Earnings common share		
Primary	\$(0.87)	\$(0.62)
Fully Diluted	\$(0.87)	\$(0.62)
Common Shares:		
Full Diluted	63,996	58,678
Year-end	64,028	63,803

LEAP THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	32,798	36,077
Operating income	(32,798)	(36,077)
Other income (expense), net	56	499
Net income	(32,078)	(33,948)
Balance for common		(34,182)
Earnings common share		
Primary	\$(0.78)	\$(1.01)
Fully Diluted	\$(0.78)	\$(1.01)
Common Shares:		
Full Diluted	41,357	33,830
Year-end	41,440	38,264

LEE ENTERPRISES, INC.**Earnings, 9 mos. to (Consol. – \$000):**

	06/29/25	06/23/24
Total Revenues	423,235	452,806
Cost & expenses	411,210	423,162
Operating income	(3,193)	8,206
Other income (expense), net	2,362	4,689
Net before taxes	(31,196)	(17,532)
Income taxes	(1,281)	(3,438)
Net income	(29,915)	(14,094)
Earnings common share		
Primary	\$(5.16)	\$(2.68)
Fully Diluted	\$(5.16)	\$(2.68)
Common Shares:		
Full Diluted	6,043	5,885
Year-end	6,264	6,191

LIFEWAY FOODS, INC.**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	99,992,000	93,791,000
Cost & expenses	92,353,000	84,571,000
Operating income	7,369,000	8,950,000
Other income (expense), net	156,000	15,000
Gains or losses	3,387,000	
Net before taxes	10,877,000	8,867,000
Income taxes	3,088,000	2,658,000
Net income	7,789,000	6,209,000
Earnings common share		
Primary	\$0.51	\$0.42
Fully Diluted	\$0.51	\$0.41
Common Shares:		
Full Diluted	15,359,000	15,176,000
Year-end	15,221,000	14,791,000

LIGHTWAVE LOGIC INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	48,522	49,772
Cost & expenses	10,559,585	12,140,217
Operating income	(10,511,063)	(12,090,445)
Other income (expense), net	836	(5,091)
Gains or losses	28,800	(3,166)
Net income	(10,369,156)	(11,699,595)
Earnings common share		
Primary	\$(0.08)	\$(0.10)
Fully Diluted	\$(0.08)	\$(0.10)

Common Shares:		
Full Diluted	124,605,324	119,552,430
Year-end	126,466,708	120,706,365

LIVEPERSON INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	124,300	165,024
Cost & expenses	136,101	229,622
Operating income	(23,377)	(66,163)
Other income (expense), net	5,967	73,452
Net before taxes	(29,804)	7,784
Income taxes	39	1,620
Net income	(29,843)	6,164
Earnings common share		
Primary	\$(0.32)	\$0.07
Fully Diluted	\$(0.37)	\$(0.70)
Common Shares:		
Full Diluted	92,867	94,973
Year-end	96,609	88,986

LUCID DIAGNOSTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	1,991,000	1,977,000
Cost & expenses	25,652,000	23,483,000
Operating income	(23,871,000)	(21,983,000)
Other income (expense), net		(681,000)
Gains or losses	(7,638,000)	890,000
Net income	(31,347,000)	(21,617,000)
Balance for common		(43,906,000)
Earnings common share		
Primary	\$(0.52)	\$(0.62)
Fully Diluted	\$(0.52)	\$(0.62)
Common Shares:		
Full Diluted	83,976,182	46,613,362
Year-end	101,826,788	49,344,945

LULU'S FASHION LOUNGE HOLDINGS INC**Earnings, 6 mos. to (Consol. – \$000):**

	06/29/25	06/30/24
Total Revenues	145,675	169,225
Cost & expenses	156,416	179,850
Operating income	(10,741)	(10,625)
Other income (expense), net	1,169	498
Net before taxes	(11,005)	(10,780)
Income taxes	(12)	5,752
Net income	(10,993)	(16,532)
Earnings common share		
Primary	\$(3.94)	\$(6.00)
Fully Diluted	\$(3.94)	\$(6.00)
Common Shares:		
Full Diluted	2,788	2,746
Year-end	2,766	2,779

LUMINAR TECHNOLOGIES INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	34,520,000	37,419,000
Cost & expenses	146,271,000	290,910,000
Operating income	(111,751,000)	(253,491,000)
Other income (expense), net	22,008,000	1,752,000
Gains or losses	5,320,000	985,000
Invest. income	2,670,000	(5,981,000)
Net before taxes	(103,293,000)	(256,300,000)
Income taxes	297,000	21,000
Net income	(103,590,000)	(256,321,000)
Balance for common		(111,192,000)
Earnings common share		
Primary	\$(2.44)	\$(0.58)
Fully Diluted	\$(2.44)	\$(0.58)
Common Shares:		
Full Diluted	45,608,362	439,454,034
Year-end	58,245,090	466,741,597

LYELL IMMUNOPHARMA INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	15	16
Cost & expenses	104,522	107,119
Operating income	(104,507)	(107,103)
Other income (expense), net	2,490	(12,556)
Net income	(94,879)	(106,476)
Earnings common share		

Primary	\$(6.42)	\$(8.40)
Fully Diluted	\$(6.42)	\$(8.40)
Common Shares:		
Full Diluted	14,774	12,741
Year-end	14,831	12,797

MACROGENICS, INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	35,434,000	19,901,000
Cost & expenses	114,815,000	131,832,000
Operating income	(79,381,000)	11,931,000
Other income (expense), net	3,093,000	5,216,000
Net before taxes	(77,182,000)	
Income taxes	105,000	
Net income	(77,287,000)	107,854,000
Earnings common share		
Primary	\$(1.23)	\$(1.73)
Fully Diluted	\$(1.23)	\$(1.73)
Common Shares:		
Full Diluted	63,051,207	62,477,108
Year-end	63,205,703	62,720,969

MANNATECH INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	52,242,000	57,133,000
Cost & expenses	54,518,000	57,455,000
Operating income	(2,276,000)	(322,000)
Other income (expense), net	(3,162,000)	1,990,000
Net before taxes	(5,613,000)	1,581,000
Income taxes	229,000	1,025,000
Net income	(5,842,000)	556,000
Earnings common share		
Primary	\$(3.07)	\$0.30
Fully Diluted	\$(3.07)	\$0.30
Common Shares:		
Full Diluted	1,901,000	1,885,000
Year-end	1,900,930	1,884,814

MARCHEX INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	23,058,000	23,646,000
Cost & expenses	25,464,000	25,380,000
Operating income	(2,406,000)	(2,035,000)
Net before taxes	(1,783,000)	(2,144,000)
Income taxes	114,000	62,000
Net income	(1,897,000)	(2,206,000)
Earnings common share		
Primary	\$(0.04)	\$(0.05)
Fully Diluted	\$(0.04)	\$(0.05)
Common Shares:		
Full Diluted	43,812,000	43,059,000
Year-end	43,908,000	43,682,000

MAREX GROUP PLC**Earnings, 6 mos. to Jun 30**(Consol. – \$Millions):

	2025	2024
Earnings common share		
Common Shares:		

MARKER THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	1,210,288	2,413,297
Cost & expenses	10,079,994	7,270,380
Operating income	(8,869,706)	(4,857,083)
Other income (expense), net	117,444	
Net income	(8,461,748)	(4,585,499)
Earnings common share		
Primary	\$(0.67)	\$(0.51)
Fully Diluted	\$(0.67)	\$(0.51)
Common Shares:		
Full Diluted	12,539,169	8,910,097
Year-end	11,300,000	8,900,000

MEDICINOVA INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	134,599	
Cost & expenses	6,944,201	6,182,489
Operating income	(6,809,602)	(6,182,489)
Other income (expense), net	3,231	(33,090)

Net income	(6,145,305)	(5,382,718)
Earnings common share		
Primary	\$(0.13)	\$(0.11)
Fully Diluted	\$(0.13)	\$(0.11)
Common Shares:		
Full Diluted	49,046,246	49,046,246
Year-end	49,046,246	49,046,246

MERIDIAN CORP**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	87,842	84,963
Operating income	10,432	7,945
Other income (expense), net	2,736	1,771
Net before taxes	10,432	7,945
Income taxes	2,441	1,943
Net income	7,991	6,002
Earnings common share		
Primary	\$0.71	\$0.54
Fully Diluted	\$0.70	\$0.54
Common Shares:		
Full Diluted	11,415	11,178
Year-end	11,297	11,191

MICROVAST HOLDINGS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	207,830,000	165,026,000
Cost & expenses	172,684,000	286,885,000
Operating income	35,146,000	121,859,000
Other income (expense), net	1,232,000	465,000
Gains or losses	(78,361,000)	(1,526,000)
Net before taxes	(44,048,000)	
Income taxes	220,000	
Net income	(44,268,000)	126,381,000
Earnings common share		
Primary	\$(0.14)	\$(0.40)
Fully Diluted	\$(0.14)	\$(0.40)
Common Shares:		
Full Diluted	323,537,551	315,438,336
Year-end	323,666,611	315,510,447

MINK THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Cost & expenses	6,753,083	6,900,995
Operating income	(7,004,448)	(6,515,101)
Other income (expense), net	(265,230)	330,915
Net income	(7,004,448)	(6,515,101)
Earnings common share		
Primary	\$(1.76)	\$(0.18)
Fully Diluted	\$(1.76)	\$(0.18)
Common Shares:		
Full Diluted	3,973,534	35,892,468
Year-end	3,990,278	39,445,520

MODULAR MEDICAL, INC**Earnings, 3 mos. to Jun 30**(Consol. – \$):

	2025	2024
Cost & expenses	6,804,000	4,220,000
Operating income	(6,804,000)	(4,220,000)
Other income (expense), net	102,000	83,000
Net income	(6,702,000)	(4,137,000)
Earnings common share		
Primary	\$(0.12)	\$(0.12)
Fully Diluted	\$(0.12)	\$(0.12)
Common Shares:		
Full Diluted	54,288,000	33,884,000
Year-end	55,275,000	32,561,000

Consolidated Balance Sheet Items, as of (\$):

Assets:	2025	
Cash & equivalents	7,522,000	
Current assets	8,292,000	
Net property & equip.	5,212,000	
Total assets	14,171,000	
Liabilities:		
Current liabilities	2,050,000	
Stockholders' equity	11,843,000	
Net current assets	6,242,000	

MOTORCAR PARTS OF AMERICA INC**Earnings, 3 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	188,364,000	169,887,000
Cost & expenses	168,295,000	176,343,000
Operating income	20,069,000	(6,456,000)
Gains or losses	(1,790,000)	2,580,000
Net before taxes	5,467,000	(18,263,000)
Income taxes	2,425,000	(178,000)
Net income	3,042,000	(18,085,000)
Earnings common share		

Primary	\$0.16	\$(0.92)
Fully Diluted	\$0.15	\$(0.92)
Common Shares:		
Full Diluted	19,917,663	19,674,539
Year-end	19,352,135	19,753,585

Consolidated Balance Sheet Items, as of (\$):

Assets:	2025	
Cash & equivalents	12,479,000	
Inventories	366,772,000	
Current assets	519,382,000	
Net property & equip.	27,885,000	
Total assets	973,350,000	
Liabilities:		
Current liabilities	360,616,000	
Long-term debt	40,844,000	
Stockholders' equity	260,113,000	
Net current assets	158,766,000	

NEUROPACE INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	46,044,000	37,380,000
Cost & expenses	58,015,000	51,155,000
Operating income	(11,971,000)	(13,775,000)
Other income (expense), net	(568,000)	171,000
Net income	(15,240,000)	(16,439,000)
Earnings common share		
Primary	\$(0.47)	\$(0.58)
Fully Diluted	\$(0.47)	\$(0.58)
Common Shares:		
Full Diluted	32,175,789	28,569,196
Year-end	33,044,371	29,139,206

NEVADA CANYON GOLD CORP**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Cost & expenses	1,377,900	1,949,090
Operating income	(1,250,692)	(1,723,448)
Gains or losses	3,305	18,674
Net income	(1,247,387)	(1,704,774)
Earnings common share		
Primary	\$(0.04)	\$(0.07)
Fully Diluted	\$(0.04)	\$(0.07)
Common Shares:		
Full Diluted	27,777,993	23,613,325
Year-end	28,148,882	26,055,343

NKARTA INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Cost & expenses	63,750,000	63,477,000
Operating income	(63,750,000)	(63,477,000)
Other income (expense), net	444,000	(4,000)
Net income	(54,960,000)	(54,511,000)
Earnings common share		
Primary	\$(0.74)	\$(0.88)
Fully Diluted	\$(0.74)	\$(0.88)
Common Shares:		
Full Diluted	73,947,220	62,088,495
Year-end	71,024,512	70,558,546

NOODLES & CO**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	07/01/25	07/02/24
Total Revenues	250,227	248,746
Cost & expenses	257,163	249,623
Operating income	(21,165)	(15,614)
Net before taxes	(26,565)	(19,590)
Income taxes	44	175
Net income	(26,609)	(19,765)
Earnings common share		
Primary	\$(0.58)	\$(0.44)
Fully Diluted	\$(0.58)	\$(0.44)
Common Shares:		
Full Diluted	45,973	45,265
Year-end	46,428	45,623

NORTHVIEW ACQUISITION CORP**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Cost & expenses	1,550,665	723,971
Operating income	(1,550,665)	(723,971)
Gains or losses	(7,839,467)	(674,497)
Net before taxes	(9,295,048)	(1,173,284)
Income taxes	21,738	44,480
Net income	(9,316,786)	(1,217,764)
Earnings common share		
Primary	\$(1.66)	\$(0.20)
Fully Diluted	\$(1.66)	\$(0.20)
Common Shares:		
Full Diluted	5,340,190	5,193,750
Year-end	5,295,527	5,931,825

NRX PHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Cost & expenses	7,577,000	13,048,000
Operating income	(7,577,000)	(13,048,000)
Other income (expense), net	(4,744,000)	(849,000)
Gains or losses	(10,777,000)	(332,000)
Net income	(23,092,000)	(14,425,000)
Earnings common share		
Primary	\$(1.34)	\$(1.49)
Fully Diluted	\$(1.34)	\$(1.49)
Common Shares:		
Full Diluted	17,176,339	9,684,873
Year-end	19,473,588	10,791,630

OMEROS CORP**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	67,323	98,191
Operating income	(67,323)	(98,191)
Other income (expense), net	(605)	6,662
Gains or losses	8,142	
Income contin. oper.	(63,455)	(108,975)
Net income	(58,884)	(93,225)
Earnings common share		
Primary	\$(1.01)	\$(1.60)
Fully Diluted	\$(1.01)	\$(1.60)
Common Shares:		
Full Diluted	58,324	58,375
Year-end	60,022	57,944

OMNITEK ENGINEERING CORP**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	965,153	504,047
Cost & expenses	920,085	628,624
Operating income	43,140	(125,978)
Other income (expense), net	70,064	(37,647)
Net before taxes	99,993	(174,014)
Income taxes	800	
Net income	99,193	(174,814)
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	21,948,091	21,948,091
Year-end	21,948,091	21,948,091

ONKURE THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	33,324	15,929
Operating income	(33,324)	(15,929)
Other income (expense), net		2,142
Net income	(31,315)	(13,787)
Earnings common share		
Primary	\$(2.33)	\$(0.41)
Fully Diluted	\$(2.33)	\$(0.41)
Common Shares:		
Full Diluted	13,467	33,421
Year-end	13,530	33,421

OID THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	6,402,000	317,000
Cost & expenses	24,025,000	38,251,000
Operating income	(17,623,000)	(37,934,000)

Other income (expense), net	2,704,000	34,760,000
Net income	(14,919,000)	(3,174,000)
Earnings common share		
Primary	\$(0.21)	\$(0.04)
Fully Diluted	\$(0.21)	\$(0.04)
Common Shares:		
Full Diluted	71,077,747	70,816,585
Year-end	71,109,514	70,971,577

OXFORD SQUARE CAPITAL CORP**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Cost & expenses	8,079,792	7,863,418
Operating income	11,603,439	14,259,462
Other income (expense), net	(859,542)	30,498,482
Invest. income	(14,480,057)	(41,267,329)
Net income	(3,736,160)	3,490,615
Earnings common share		
Primary	\$(0.05)	\$0.06
Fully Diluted	\$(0.05)	\$0.06
Common Shares:		
Full Diluted	71,622,922	60,146,853
Year-end	76,236,738	62,705,628

PIXELWORKS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	15,344	24,589
Cost & expenses	30,741	40,824
Operating income	(15,397)	(16,235)
Other income (expense), net	814	
Net before taxes	(14,420)	(15,474)
Income taxes	525	137
Net income	(14,945)	(15,611)
Earnings common share		
Primary	\$(2.80)	\$(3.12)
Fully Diluted	\$(2.80)	\$(3.12)
Common Shares:		
Full Diluted	5,166	4,818
Year-end	5,319	4,873

PLAYBOY INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	57,023,000	53,204,000
Cost & expenses	69,166,000	71,324,000
Operating income	(12,143,000)	(18,120,000)
Other income (expense), net	1,202,000	(295,000)
Net before taxes	(14,736,000)	(31,430,000)
Income taxes	1,984,000	1,669,000
Net income	(16,720,000)	(33,099,000)
Earnings common share		
Primary	\$(0.18)	\$(0.45)
Fully Diluted	\$(0.18)	\$(0.45)
Common Shares:		
Full Diluted	93,549,044	72,859,533
Year-end	94,665,825	73,253,845

PRELUDE THERAPEUTICS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	66,800	71,507
Operating income	(66,800)	(71,507)
Other income (expense), net	3,484	5,336
Net income	(63,316)	(66,171)
Earnings common share		
Primary	\$(0.83)	\$(0.87)
Fully Diluted	\$(0.83)	\$(0.87)
Common Shares:		
Full Diluted	75,990	75,749
Year-end	56,594	55,008

PREMIER INC**Annual Report****Consolidated Income Statement, Years Ended Jun. 30**
(\$000):

	2025	2024	2023
		(revised)	(revised)
Other services and support	556,328	624,168	480,297
Other services and support	456,319	511,841	...
Products	...	...	615,040
Net revenue	1,012,647	1,136,009	1,095,337

Cost of revenue - services & software licenses	269,288	268,885	...
Services and software licenses	...	...	218,087
Cost of revenue	269,288	268,885	218,087
Gross profit	743,359	867,124	877,250
Selling, general & administrative	701,420	690,337	581,016
Research & development	2,634	3,115	4,540
Amortization of purchased intangible assets	38,189	47,026	47,561
Operating expenses	742,243	740,478	633,117
Operating income	1,116	126,646	244,133
Equity in net income of unconsolidated affiliates	11,972	(295)	16,068
Interest & investment income (loss), net	(17,223)	(662)	(14,647)
Other income (expense), net	102,184	20,832	6,306
Other income (expense), net	96,933	19,875	7,727
Income (loss) before income taxes	98,049	146,521	251,860
Current federal tax expense	(1,258)	131,548	673
Current state tax expense	(503)	34,030	3,016
Total current tax expense	(1,761)	165,578	3,689
Deferred federal tax expense	24,290	(104,194)	55,137
Deferred state tax expense (benefit)	2,785	(19,082)	17,257
Total deferred tax expense (benefit)	27,076	(123,276)	72,394
Income tax expense (benefit)	25,315	42,302	76,083
Net income (loss) from continuing operations	72,734	104,219	175,777
Discontinued Operations before Tax - Income/Expense	(56,397)	3,269	(1,862)
Discontinued Operations - Tax Impacts - Current Income/Expense	14,496	(769)	972
Income (loss) from discontinued operations, net of tax	(41,901)	2,500	(890)
Net income (loss)	30,833	106,719	174,887
Net income (loss) attributable to Premier Healthcare Solutions, Inc. shareholders	20,269	119,544	175,026
Weighted average shares outstanding - basic	91,228	113,791	118,767
Weighted average shares outstanding - diluted	91,917	114,408	119,889
Year end shares outstanding	82,544	105,027	119,158
Earnings (loss) per share from continuing operations - basic	\$0.68	\$1.03	\$1.48
Earnings per share-inc from discontinued oper	\$(0.46)	\$0.02	\$(0.01)
Earnings (loss) per share from discontinued operations - basic	\$(0.46)	\$0.02	\$(0.01)
Net earnings (loss)			

per share - basic	\$0.22	\$1.05	\$1.47
Earnings (loss) per share from continuing operations - diluted	\$0.68	\$1.02	\$1.47
Earn per share-inc from discount opers - diluted	\$(0.46)	\$0.02	\$(0.01)
Earnings (loss) per share from discontinued operations - diluted	\$(0.46)	\$0.02	\$(0.01)
Net earnings (loss) per share - diluted	\$0.22	\$1.04	\$1.46
Dividends Per Share - Common - Gross - by Period End Date ..	\$1.05	\$0.84	\$0.83
Full-Time Employees (Period End)	2,700	2,900	2,800
Total number of employees	2,700	...	...
Number of class A common stockholders ..	81	...	...
Net Income Before Extraordinary and Preferred Dividends ..	72,734	104,219	175,777

□ Restated to reflect discontinued operations

Consolidated Balance Sheet, Years Ended Jun. 30 (\$000):			
	2025	2024	(revised)
Cash and cash equivalents	83,725	125,146	
Other accounts receivable	99,092	100,965	
Less: allowance for doubtful accounts	6,339	1,392	
Prepaid expenses & other current assets	318,337	335,831	
Current assets of discontinued operations	...	119,662	
Prepaid expenses and other current assets	84,649	73,653	
Total current assets	585,803	755,257	
Capitalized software	67,204	64,761	
Computer hardware	928,036	856,730	
Furniture & other equipment	7,062	7,061	
Leasehold improvements	19,222	19,222	
Total property & equipment	1,021,524	947,774	
Less: accumulated depreciation & amortization	820,043	742,063	
Property and equipment	201,481	205,711	
Goodwill	897,894	995,852	
Deferred income tax assets	762,859	773,002	
Deferred compensation plan assets	35,069	54,422	
Investments in unconsolidated affiliates	262,621	228,562	
Operating lease right-of-use assets	5,072	20,635	
Other assets	95,505	98,749	
Intangible assets	250,770	269,259	
Total assets	3,097,074	3,401,449	
Revenue share obligations	347,306	292,792	
Accounts payable	19,619	22,610	
Accrued expenses	59,151	58,482	
Accrued compensation & benefits	99,019	100,395	
Deferred revenue	22,548	19,642	
Current portion of notes payable to former limited partners	...	101,523	
Line of credit & current portion of long-term debt	280,000	1,008	
Other current liabilities	33,182	52,589	
Current liabilities of discontinued operations	96	45,724	
Current portion of liability related to the sale of future revenues	49,712	51,798	

Total current liabilities	910,633	746,563
Long-term debt, less current portion	590,727	599,423
Operating lease liabilities, less current portion	2,007	11,170
Deferred compensation plan obligations	35,069	54,422
Total liabilities	1,566,497	1,439,218
Class A common stock	916	1,115
Treasury stock, at cost	161,561	250,129
Additional paid-in capital	2,176,318	2,105,684
Retained earnings	(485,045)	105,590
Accumulated other comprehensive loss	(51)	(29)
Total stockholders' equity (deficit)	1,530,577	1,962,231
Total stockholders equity	1,530,577	1,962,231

Recent Dividends:

1. Premier Inc class B common.

No dividends paid.

2. Premier Inc class A common.

No dividends paid.

Annual Dividends:

1. Premier Inc class B common.

No dividends paid.

2. Premier Inc class A common.

No dividends paid.

PROFICIENT AUTO LOGISTICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2025	2024
Total Revenues	210,752,607	97,126,285
Cost & expenses	193,983,725	115,015,752
Operating income	(2,237,148)	(23,321,486)
Other income (expense), net	(130,516)	169,147
Net before taxes	(5,776,460)	(24,509,565)
Income taxes	(1,027,942)	(4,144,562)
Net income	(4,748,518)	(20,365,003)
Earnings common share		
Primary	\$(0.17)	\$(0.78)
Fully Diluted	\$(0.17)	\$(0.78)
Common Shares:		
Full Diluted	27,341,813	25,960,435
Year-end	27,738,985	25,960,435

PYXIS ONCOLOGY INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2025	2024
Total Revenues	2,820	16,146
Cost & expenses	45,484	41,783
Operating income	(42,664)	(25,637)
Other income (expense), net	1,199	1,507
Net before taxes	(39,229)	
Income taxes	283	
Net income	(39,512)	(20,557)
Earnings common share		
Primary	\$(0.64)	\$(0.37)
Fully Diluted	\$(0.64)	\$(0.37)
Common Shares:		
Full Diluted	61,486	55,892
Year-end	62,018	58,915

RAPID MICRO BIOSYSTEMS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2025	2024
Total Revenues	14,467	12,229
Cost & expenses	38,276	39,880
Operating income	(23,809)	(27,651)
Other income (expense), net	(111)	(52)
Net before taxes	(23,103)	(25,882)
Income taxes	18	18
Net income	(23,121)	(25,900)
Earnings common share		
Primary	\$(0.52)	\$(0.60)
Fully Diluted	\$(0.52)	\$(0.60)
Common Shares:		
Full Diluted	44,322	43,431
Year-end	44,060	42,906

RCM TECHNOLOGIES, INC.

Earnings, 6 mos. to (Consol. - \$):

	06/28/25	06/29/24
Total Revenues	162,639,000	141,103,000
Cost & expenses	148,630,000	128,738,000
Operating income	13,184,000	11,655,000
Net before taxes	11,557,000	10,655,000
Income taxes	3,586,000	2,941,000
Net income	7,971,000	7,714,000
Earnings common share		
Primary	\$1.06	\$0.98
Fully Diluted	\$1.04	\$0.95
Common Shares:		
Full Diluted	7,650,272	8,078,049
Year-end	7,390,385	7,666,709

RED ROBIN GOURMET BURGERS INC

Earnings, 6 mos. to (Consol. - \$):

	07/13/25	07/14/24
Total Revenues	676,055,000	688,695,000
Cost & expenses	630,165,000	663,811,000
Operating income	18,877,000	(6,672,000)
Net before taxes	5,143,000	(18,808,000)
Income taxes	(99,000)	141,000
Net income	5,242,000	(18,949,000)
Earnings common share		
Primary	\$0.30	\$(1.21)
Fully Diluted	\$0.28	\$(1.21)
Common Shares:		
Full Diluted	18,598,000	15,608,000
Year-end	17,886,000	15,755,000

RGC RESOURCES, INC.

Earnings, 9 mos. to Jun 30(Consol. - \$):

	2025	2024
Total Revenues	81,016,198	71,536,930
Cost & expenses	53,482,203	46,604,470
Operating income	18,924,523	16,839,339
Other income (expense), net	3,608,439	3,120,747
Net before taxes	17,610,003	15,190,107
Income taxes	4,125,694	3,570,033
Net income	13,484,309	11,620,074
Earnings common share		
Primary	\$1.31	\$1.15
Fully Diluted	\$1.31	\$1.15
Common Shares:		
Full Diluted	10,298,688	10,132,347
Year-end	10,323,956	10,193,160

SAGA COMMUNICATIONS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2025	2024
Total Revenues	52,441	
Cost & expenses	50,737	53,680
Operating income	(889)	(274)
Other income (expense), net	24	1,133
Net before taxes	(647)	1,299
Net income	(447)	924
Balance for common	(426)	895
Earnings common share		
Primary	\$(0.07)	\$0.15
Fully Diluted	\$(0.07)	\$0.15
Common Shares:		
Full Diluted	6,138	6,068
Year-end	6,418	6,252

SALEM MEDIA GROUP, INC.

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2025	2024
Total Revenues	105,853	119,220
Cost & expenses	132,175	109,226
Operating income	(31,643)	3,652
Other income (expense), net	542	9
Net before taxes	(31,764)	(3,975)
Income taxes	(7,041)	(1,090)
Net income	(24,723)	(2,885)
Earnings common share		
Primary	\$(0.81)	\$(0.11)
Fully Diluted	\$(0.81)	\$(0.11)
Common Shares:		
Full Diluted	30,507	27,217
Year-end	31,863	27,217

SAVARA INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2025	2024
Cost & expenses	59,811,000	45,600,000
Operating income	(59,874,000)	(45,665,000)
Other income (expense), net	238,000	797,000
Net income	(57,040,000)	(42,589,000)
Earnings common share		
Primary	\$(0.26)	\$(0.23)
Fully Diluted	\$(0.26)	\$(0.23)
Common Shares:		
Full Diluted	216,289,923	182,567,091
Year-end	172,836,922	138,199,047

SBC MEDICAL GROUP HOLDINGS INCORP**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	90,687,548	107,910,122
Cost & expenses	51,931,282	56,158,677
Operating income	38,756,266	51,751,445
Other income (expense), net	6,101,513	(1,295,320)
Gains or losses	111,632	3,813,609
Net before taxes	44,991,768	54,288,635
Income taxes		16,981,094
Net income	23,931,802	37,307,541
Earnings common share		
Primary	\$0.23	\$0.32
Fully Diluted	\$0.23	\$0.32
Common Shares:		
Full Diluted	103,392,580	116,382,441
Year-end	103,098,442	116,382,441

SCYNEXIS, INC.**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	1,620	2,109
Cost & expenses	19,810	20,854
Operating income	(18,190)	(18,745)
Gains or losses	5,094	4,044
Net before taxes		(13,524)
Income taxes		523
Net income	(12,276)	(14,047)
Earnings common share		
Primary	\$(0.25)	\$(0.29)
Fully Diluted	\$(0.25)	\$(0.29)
Common Shares:		
Full Diluted	49,594	48,379
Year-end	39,175	37,856

SEER INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	8,256	6,138
Cost & expenses	49,517	58,426
Operating income	(41,261)	(52,288)
Other income (expense), net	(4,171)	(260)
Net before taxes	(39,223)	
Income taxes	149	
Net income	(39,372)	(43,529)
Earnings common share		
Primary	\$(0.67)	\$(0.67)
Fully Diluted	\$(0.67)	\$(0.67)
Common Shares:		
Full Diluted	58,744	64,581
Year-end	56,329	63,226

SHATTUCK LABS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues		2,724
Cost & expenses	27,421	45,730
Operating income	(27,421)	(43,006)
Other income (expense), net	1,261	2,950
Net income	(26,160)	(40,056)
Earnings common share		
Primary	\$(0.51)	\$(0.79)
Fully Diluted	\$(0.51)	\$(0.79)
Common Shares:		
Full Diluted	50,984	50,679
Year-end	47,903	47,727

SMART SAND INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	151,328	156,852
Cost & expenses	157,232	151,195

Operating income	(7,127)	4,312
Other income (expense), net	195	(1,139)
Net before taxes	(7,590)	2,291
Income taxes	(4,755)	2,937
Net income	(2,835)	(646)
Earnings common share		
Primary	\$(0.07)	\$(0.02)
Fully Diluted	\$(0.07)	\$(0.02)
Common Shares:		
Full Diluted	39,232	38,639
Year-end	38,654	38,771

SMARTKEM INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	55,000	40,000
Cost & expenses	7,565,000	5,266,000
Operating income	(7,510,000)	(5,226,000)
Gains or losses		672,000
Net before taxes	(4,558,000)	(4,794,000)
Income taxes	(24,000)	1,000
Net income	(4,534,000)	(4,795,000)
Balance for common	(4,534,000)	(11,889,000)
Earnings common share		
Primary	\$(0.62)	\$(4.04)
Fully Diluted	\$(0.62)	\$(4.04)
Common Shares:		
Full Diluted	7,364,145	2,946,354
Year-end	4,441,165	1,721,900

SPARTANNASH CO**Earnings, 6 mos. to (Consol. – \$):**

	07/12/25	07/13/24
Total Revenues	5,180,769,000	5,037,019,000
Cost & expenses	5,143,684,000	4,980,277,000
Operating income	37,085,000	56,742,000
Other income (expense), net	459,000	1,598,000
Net before taxes	10,052,000	34,312,000
Income taxes	1,782,000	9,852,000
Net income	8,270,000	24,460,000
Balance for common	8,228,000	24,315,000
Earnings common share		
Primary	\$0.24	\$0.72
Fully Diluted	\$0.24	\$0.71
Common Shares:		
Full Diluted	34,234,000	34,329,000
Year-end	33,858,000	33,750,000

SPRUCE BIOSCIENCES INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues		3,612
Cost & expenses	17,184	26,281
Operating income	(17,184)	(22,669)
Other income (expense), net	1,141	2,043
Net income	(16,108)	(20,806)
Earnings common share		
Primary	\$(27.36)	\$(38.25)
Fully Diluted	\$(27.36)	\$(38.25)
Common Shares:		
Full Diluted	589	548
Year-end	563	551

STANDARD BIOTOOLS INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	41,984	44,145
Cost & expenses	94,651	118,850
Operating income	(52,667)	(74,705)
Other income (expense), net	5,530	23,391
Net before taxes	(41,771)	(41,696)
Income taxes	(728)	152
Income contin. oper.	(41,043)	(41,848)
Net income	(59,492)	(77,875)
Balance for common	(59,492)	(123,889)
Earnings common share		
Primary	\$(0.16)	\$(0.37)
Fully Diluted	\$(0.16)	\$(0.37)
Common Shares:		
Full Diluted	379,369	333,228
Year-end	381,693	371,123

STEREOTAXIS INC**Earnings, 6 mos. to Jun 30(Consol. – \$):**

	2025	2024
Total Revenues	16,270,000	11,382,000
Cost & expenses	26,176,000	22,149,000
Operating income	(9,906,000)	(10,767,000)
Other income (expense), net	(1,000)	(3,000)
Net income	(9,649,000)	(10,340,000)
Balance for common	(10,281,000)	(10,996,000)
Earnings common share		
Primary	\$(0.12)	\$(0.13)
Fully Diluted	\$(0.12)	\$(0.13)
Common Shares:		
Full Diluted	87,861,231	84,025,335
Year-end	86,000,849	82,986,144

SYNCHRONOSS TECHNOLOGIES INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	84,699	86,423
Cost & expenses	61,130	69,163
Operating income	15,089	8,873
Other income (expense), net	(6,666)	5,031
Net before taxes	(20,880)	7,292
Income taxes	2,541	3,311
Net income	(23,421)	3,981
Balance for common	(23,421)	2,419
Earnings common share		
Primary	\$(2.27)	\$0.24
Fully Diluted	\$(2.27)	\$0.24
Common Shares:		
Full Diluted	10,336	10,265
Year-end	11,497	10,815

SYNLOGIC INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues		8
Cost & expenses	1,675	38,434
Operating income	(1,675)	(38,426)
Other income (expense), net		(2)
Gains or losses	1,094	14,958
Net before taxes		(22,523)
Income taxes		5
Net income	(212)	(22,528)
Earnings common share		
Primary	\$(0.02)	\$(1.85)
Fully Diluted	\$(0.02)	\$(1.85)
Common Shares:		
Full Diluted	12,301	12,168
Year-end	11,699	11,699

SYPRIS SOLUTIONS, INC.**Earnings, 6 mos. to (Consol. – \$000):**

	06/29/25	06/30/24
Total Revenues	60,934	71,074
Cost & expenses	62,505	71,175
Operating income	(1,571)	(101)
Other income (expense), net	(389)	(535)
Net before taxes	(2,643)	(1,558)
Income taxes	307	647
Net income	(2,950)	(2,205)
Balance for common	(2,950)	(2,205)
Earnings common share		
Primary	\$(0.13)	\$(0.10)
Fully Diluted	\$(0.13)	\$(0.10)
Common Shares:		
Full Diluted	22,214	21,973
Year-end	23,030	23,024

TALPHERA INC**Earnings, 6 mos. to Jun 30(Consol. – \$000):**

	2025	2024
Total Revenues	27	
Cost & expenses	6,636	8,507
Operating income	(6,609)	(7,234)
Other income (expense), net		(394)
Gains or losses	302	699
Income contin. oper.	(6,155)	
Net income	(6,082)	(7,781)
Earnings common share		
Primary	\$(0.20)	\$(0.31)
Fully Diluted	\$(0.20)	\$(0.31)
Common Shares:		
Full Diluted	30,422	25,462
Year-end	20,523	16,993

THERAPEUTICSMD INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	1,345,000	547,000
Cost & expenses	3,130,000	3,816,000
Operating income	(1,976,000)	(3,582,000)
Other income (expense), net	1,857,000	1,728,000
Net before taxes	(123,000)	
Income taxes	(32,000)	
Income contin. oper.	(91,000)	(1,859,000)
Net income	(102,000)	(1,824,000)
Earnings common share		
Primary	\$(0.01)	\$(0.16)
Fully Diluted	\$(0.01)	\$(0.16)
Common Shares:		
Full Diluted	11,563,000	11,532,000
Year-end	11,574,000	11,532,000

TRANSACT TECHNOLOGIES INC.**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	26,851	22,286
Cost & expenses	27,124	24,025
Operating income	(273)	(1,739)
Other income (expense), net	178	(53)
Net before taxes	(33)	(1,718)
Income taxes	91	(363)
Net income	(124)	(1,355)
Earnings common share		
Primary	\$(0.01)	\$(0.14)
Fully Diluted	\$(0.01)	\$(0.14)
Common Shares:		
Full Diluted	10,064	9,985
Year-end	10,092	9,998

TRAVELZOO**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	47,046,000	43,126,000
Cost & expenses	41,182,000	33,524,000
Operating income	5,864,000	9,602,000
Other income (expense), net	790,000	315,000
Net before taxes	6,654,000	9,917,000
Income taxes	1,912,000	2,772,000
Net income	4,742,000	7,145,000
Earnings common share		
Primary	\$0.39	\$0.54
Fully Diluted	\$0.38	\$0.54
Common Shares:		
Full Diluted	12,088,000	13,300,000
Year-end	11,081,000	12,402,000

TYRA BIOSCIENCES INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Cost & expenses	63,302	45,853
Operating income	(63,302)	(45,853)
Net income	(56,245)	(36,894)
Earnings common share		
Primary	\$(0.95)	\$(0.67)
Fully Diluted	\$(0.95)	\$(0.67)
Common Shares:		
Full Diluted	59,443	55,449
Year-end	53,233	52,736

UNITED HEALTH PRODUCTS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Cost & expenses	1,757,572	830,271
Operating income	(1,757,572)	(830,271)
Net income	(1,846,846)	(883,959)
Earnings common share		
Primary	\$(0.01)	
Fully Diluted	\$(0.01)	
Common Shares:		
Full Diluted	255,684,472	246,734,321
Year-end	257,133,222	248,233,222

UNIVERSAL ELECTRONICS INC.**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	189,991,000	182,352,000
Cost & expenses	192,737,000	193,713,000
Operating income	(2,746,000)	(11,361,000)

Other income (expense), net	(775,000)	74,000
Net before taxes	(5,156,000)	(13,295,000)
Income taxes	4,030,000	3,547,000
Net income	(9,186,000)	(16,842,000)
Earnings common share		
Primary	\$(0.70)	\$(1.30)
Fully Diluted	\$(0.70)	\$(1.30)
Common Shares:		
Full Diluted	13,141,000	12,909,000
Year-end	13,318,398	12,972,114

UTAH MEDICAL PRODUCTS, INC.**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2025	2024
Total Revenues	19,663,000	21,740,000
Cost & expenses	13,314,000	14,419,000
Operating income	6,349,000	7,321,000
Other income (expense), net	1,345,000	1,689,000
Net before taxes	7,694,000	9,010,000
Income taxes	1,605,000	1,601,000
Net income	6,089,000	7,409,000
Earnings common share		
Primary	\$1.86	\$2.07
Fully Diluted	\$1.86	\$2.07
Common Shares:		
Full Diluted	3,278,000	3,579,000
Year-end	3,216,000	3,499,000

VERRICA PHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30**(Consol. – \$000):

	2025	2024
Total Revenues	16,141	9,003
Cost & expenses	22,761	42,808
Operating income	(6,620)	(33,805)
Other income (expense), net	(1)	(16)
Gains or losses	852	
Net income	(9,538)	(37,517)
Earnings common share		
Primary	\$(1.01)	\$(8.10)
Fully Diluted	\$(1.01)	\$(8.10)
Common Shares:		
Full Diluted	9,486	4,649
Year-end	9,255	4,246

VIAVI SOLUTIONS INC**Annual Report****Consolidated Income Statement, Years Ended (\$000):**

	06/28/25	06/29/24	07/01/23
Product revenue	912,000	834,800	936,100
Service revenue	172,300	165,600	170,000
Total net revenues	1,084,300	1,000,400	1,106,100
Service cost of revenue			77,800
Cost of sales			364,900

Amortization of acquired technologies	19,500	13,800	24,600
Total cost of revenues	463,200	424,500	467,300
Gross profit (loss)	621,100	575,900	638,800
Research & development expenses	208,700	201,900	206,900
Selling, general & administrative expenses	349,400	333,300	328,700
Amortization of other intangibles	4,800	6,300	8,700
Restructuring and related charges (benefits)	700	13,600	
Restructuring charges			12,100
Total operating expenses	563,600	555,100	556,400
Income (loss) from operations	57,500	20,800	82,400
Interest income	13,100	18,900	10,200
Foreign exchange gains (losses), net	(1,700)	(3,100)	
Foreign exchange gain (loss), net			(2,200)
Other income, net			(400)

Interest Expense	30,000	30,900	
Interest expense			27,100
Gain on litigation settlement		(7,300)	
Other income (expense), net	(300)	(1,400)	
Income (loss) before income taxes	38,600	11,600	60,700
Current	(7,700)	3,300	2,600
Current	41,000	32,800	27,600
Deferred	(3,900)	1,000	5,000
Current Tax - Federal		300	
Net Income After Taxes	34,200	(25,800)	
Deferred Tax - Federal	(23,200)		
Deferred Tax - State	(1,800)		
Provision for income taxes	4,400	37,400	35,200
Net income (loss)	34,800	(25,800)	25,500
Weighted average shares outstanding - basic	222,500	222,600	224,600
Weighted average shares outstanding - diluted	225,700	222,600	226,600
Year end shares outstanding	223,000	222,000	222,000
Net income (loss) per share - basic	\$0.16	\$(0.12)	\$0.11
Net income (loss) per share - diluted	\$0.15	\$(0.12)	\$0.11
Full-Time Employees	3,600	3,600	
Total number of employees	3,600	3,600	3,600
Number of common stockholders	1,392	1,569	1,747
Foreign currency translation adjustments			18,800
Cost of revenues	366,200	335,200	
Service cost of revenue	77,500	75,500	
Loss on convertible note modification			(2,200)
Net income			25,500
Basic EPS Excluding ExtraOrdinary Items	\$0.16	\$(0.12)	
Diluted EPS Excluding ExtraOrd Items	\$0.15	\$(0.12)	
Equity Earnings - Net of Tax	600		

Consolidated Balance Sheet, Years Ended (\$000):

	06/28/25	06/29/24
Cash and cash equivalents	423,600	471,300
Short-term investments	1,700	19,900
Restricted cash	3,700	5,000
Accounts receivable, gross	262,900	214,700
Year Ended July 1, 2023	1,900	1,600
Accounts receivable, net	261,000	213,100
Finished goods	52,500	44,600
Work in process	18,300	15,400
Raw materials	47,100	36,500
Inventories, net	117,900	96,500
Refundable income taxes	32,000	28,500
Prepayments	21,900	18,500
Assets held for sale		2,500
Advances to contract manufacturers	5,800	5,700
Transaction tax receivables	12,500	3,300
Prepayments and other current assets	77,300	70,700
Fair value of forward contracts	4,900	1,700
Transaction tax receivables	200	
Total current assets	885,200	876,500

Land	19,900	19,500
Buildings & improvements	79,600	74,900
Machinery & equipment	400,500	378,600
Furniture, fixtures, software & office equipment	67,800	70,700
Leasehold improvements	75,900	73,000
Construction in progress	26,500	20,000
Property, plant & equipment, gross	670,200	636,700
Less: accumulated depreciation & amortization	...	408,500
Accumulated depreciation	438,300	...
Property, plant and equipment, net	231,900	228,200
Goodwill, net	595,700	452,900
Intangibles, net	...	38,200
Deferred income taxes	87,200	82,500
Intangibles, net	131,600	...
Long-term investments	3,000	...
Deferred contract cost	3,000	...
Debt issuance cost - revolving credit facility	1,400	...
Deposits	2,400	...
Other non-current assets	13,400	...
Operating ROU assets (Other non-current assets)	34,100	...
Restricted Cash - Long-Term	4,900	...
Total assets	1,993,800	1,736,300
Accounts Payable	68,800	50,400
Short-term debt	246,200	...
Accrued payroll and related expenses	63,600	48,200
Deferred revenue	74,100	65,700
Accrued expenses	28,700	25,300
Other current liabilities	108,300	57,500
Total current liabilities	589,700	247,100
Long-term debt	396,300	636,000
Financing obligation	15,500	15,700
Deferred income taxes	6,000	11,700
Pension & post-employment benefits	54,100	51,200
Financing obligation	...	7,300
Long-term deferred revenue	28,200	25,700
Operating lease liabilities	24,100	25,700
Uncertain tax position	11,400	17,000
Warranty accrual	800	4,000
Other non-current liabilities	227,600	800
Asset retirement obligations	3,500	3,000
Fair value of contingent consideration	75,900	9,500
Common stock	200	200
Additional paid-in capital	70,517,900	70,471,900
Accumulated deficit	(69,628,100)	(69,646,500)
Unrealized gains (losses) on available-for-sale investments	(5,300)	(5,300)
Foreign currency translation adjustments	(97,500)	(131,400)
Change in unrealized components of defined benefit obligations, net of tax	(109,800)	(144,000)
Ending balance as of July 1, 2023	(7,000)	(7,300)
Total stockholders' equity	780,200	681,600
Other	8,100	...
Total Liabilities	1,213,600	...
Total Equity	780,200	681,600

Recent Dividends:

- 1. Viavi Solutions Inc preferred.**
No dividends paid.
- 2. Viavi Solutions Inc common.**
No dividends paid.

Annual Dividends:

- 1. Viavi Solutions Inc preferred.**
No dividends paid.
- 2. Viavi Solutions Inc common.**
No dividends paid.

VROOM INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Cost & expenses	13,964	73,958
Operating income	29,922	(63,512)
Net before taxes	29,922	(63,512)
Income taxes	214	269
Income contin. oper.	29,708	(63,781)
Net income	30,216	(88,806)
Earnings common share		
Primary	\$5.85	\$(49.41)
Fully Diluted	\$5.85	\$(49.41)
Common Shares:		
Full Diluted	5,169	1,797
Year-end	5,200	1,807

VTV THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	1,000	1,000
Cost & expenses	14,224	13,782
Operating income	(14,224)	(12,782)
Other income (expense), net	(5)	72
Gains or losses	26	(250)
Net before taxes	(12,328)	(12,782)
Income taxes	100	100
Net income	(13,597)	(12,428)
Earnings common share		
Primary	\$(1.69)	\$(1.97)
Fully Diluted	\$(1.69)	\$(1.97)
Common Shares:		
Full Diluted	6,585	5,099
Year-end	2,617	2,433

VYCOR MEDICAL INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Total Revenues	932,731	743,246
Cost & expenses	864,630	706,839
Operating income	38,340	6,646
Other income (expense), net	4,544	4,544
Income contin. oper.	(12,801)	(40,496)
Net income	(14,676)	(40,646)
Balance for common	(176,861)	(202,831)
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	33,372,796	32,628,835
Year-end	33,372,796	32,628,835

VYNE THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	271	296
Cost & expenses	17,009	18,072
Operating income	(16,738)	(17,776)
Other income (expense), net	2,388	2,140
Income contin. oper.	(14,350)	(15,636)
Net income	(14,366)	(15,655)
Earnings common share		
Primary	\$(0.34)	\$(0.37)
Fully Diluted	\$(0.34)	\$(0.37)
Common Shares:		
Full Diluted	42,716	42,584
Year-end	19,774	14,536

WELSBACH TECHNOLOGY METALS ACQUISITION CORP**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Cost & expenses	1,211,136	649,654
Operating income	(1,211,136)	(649,654)
Net before taxes	(1,015,767)	(130,334)
Income taxes	25,650	35,098
Net income	(1,041,417)	(165,432)
Earnings common share		
Primary	\$(0.31)	\$(0.04)
Fully Diluted	\$(0.31)	\$(0.04)

Common Shares:

Full Diluted	3,344,804	4,444,848
Year-end	2,373,029	3,366,765

WEREWOLF THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Cost & expenses	35,533,000	38,007,000
Operating income	(35,533,000)	(36,122,000)
Other income (expense), net	179,000	1,059,000
Net income	(36,071,000)	(33,442,000)
Earnings common share		
Primary	\$(0.80)	\$(0.79)
Fully Diluted	\$(0.80)	\$(0.79)
Common Shares:		
Full Diluted	44,904,880	42,564,342
Year-end	45,335,265	43,702,147

XILIO THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	11,014	2,357
Cost & expenses	39,231	34,548
Operating income	(28,217)	(32,191)
Other income (expense), net	(842)	1,063
Gains or losses	(50)	...
Net income	(29,109)	(31,128)
Earnings common share		
Primary	\$(0.34)	\$(0.73)
Fully Diluted	\$(0.34)	\$(0.73)
Common Shares:		
Full Diluted	85,634	42,836
Year-end	51,828	43,952

XOMA ROYALTY CORP**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2025	2024
Total Revenues	29,041	...
Cost & expenses	17,310	29,659
Operating income	10,532	(17,083)
Other income (expense), net	7,729	22,791
Gains or losses	...	8,635
Net income	11,558	7,390
Balance for common	6,225	3,253
Earnings common share		
Primary	\$0.52	\$0.28
Fully Diluted	\$0.50	\$0.27
Common Shares:		
Full Diluted	17,777	17,263
Year-end	12,062	11,658

XTANT MEDICAL HOLDINGS INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2025	2024
Total Revenues	68,315,000	57,816,000
Cost & expenses	62,628,000	64,232,000
Operating income	5,687,000	(6,416,000)
Other income (expense), net	(2,000)	7,000
Net before taxes	3,838,000	(8,157,000)
Income taxes	230,000	104,000
Net income	3,608,000	(8,261,000)
Earnings common share		
Primary	\$0.03	\$(0.06)
Fully Diluted	\$0.02	\$(0.06)
Common Shares:		
Full Diluted	148,339,423	130,291,796
Year-end	139,315,722	130,314,372

*

MERGENT OTC INDUSTRIAL News Reports 0027-0865 is published weekly online on Tuesdays and printed the last Friday of the month by Mergent, Inc., 444 Madison Ave., New York, NY 10022. The News Reports are part of the OTC INDUSTRIAL Manual and provide periodic updates. Send address changes to MERGENT OTC INDUSTRIAL, 580 Kingsley Park Drive, Fort Mill, SC 29715.

Copyright©2025 by Mergent. All information contained herein is copyrighted in the name of Mergent, Inc., and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, in whole or in part, in any form or matter or by any means whatsoever, by any person without Mergent's prior written consent.

All information contained is obtained by Mergent, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error, as well as other factors, however, such information is provided "as is", without warranty of any kind. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY INFORMATION IS GIVEN OR MADE BY MERGENT IN ANY FORM OR MANNER WHATSOEVER. Under no circumstances shall Mergent have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analyzing, editing, transcribing, transmitting, communicating or delivering any such information, or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if Mergent is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, any such information.